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ABSTRACT OF THESIS
AN ELECTROCHEMICAL, FLUIDIC, CHIP-BASED BIOSENSOR
FOR BIOMARKER DETECTION
Biosensors and their use in both the research and clinical field for the detection and
monitoring of critical biomarkers are prevalent and constantly improving. However,
continued research needs to be done to address shortcomings, such as low sensitivity, poor
specificity, and poor readiness for integration into research use and patient care. The
objective of this research was to create a combined fluidic, chip-based biosensor that could
detect different biomarkers with high sensitivity and ease of use. For assessing the
developed sensor, three separate biomarkers were tested: glucose, cholesterol, and oxygen.
Both the glucose biosensor and cholesterol biosensor were combined with the microfluidic
platform for biomarker detection testing. The oxygen biosensor was tested as a stand-alone
chip, with future work including the combination with the microfluidic platform. Results
of stepwise, amperometric tests prove the success of the microfluidic, chip-based biosensor
for both glucose and cholesterol detection within the respective physiological ranges, with
the glucose biosensor showing high sensitivity and a low limit of detection. The oxygen
biosensor also proved successful in detecting changes in oxygen concentration in solution
within physiological ranges of arterial oxygen partial pressure.
KEYWORDS: Amperometric Biosensor, Enzymatic Biosensor, Microfluidics, In-Situ
Biomarker Detection, Continuous Monitoring
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CHAPTER 1.
1.1

INTRODUCTION

Overview of Biosensors
Biosensors are analytical devices that convert a biological reaction into a

measurable and processable signal. A biosensor is typically regarded as made of three
components: the sample, the transducer and the electronic system. However, the function
of a biosensor is better understood by breaking down the structure further and dividing it
into five parts, shown as parts a) through e) in Figure 1.1. The first part is recognition
molecules, like bioreceptors that bind specifically to the analyte used or enzymes that
facilitate a specific reaction. The second part is an interface where a particular biological
binding or reaction event occurs and produces a signal, such as the electrodes on a screen
printed electrode chip. The third part is a transducer element that converts and amplifies a
biological event into physical, electronic signals. The fourth part is a computer software
that processes the signal and coverts it to a quantitative parameter and the fifth part is an
interface that presents the resulting quantity to the user (Grieshaber et al., 2008). Potential
components of each of these parts and their interaction is shown in Figure 1.1. This creates
the basic structure of a biosensor with each component depending on the type of sensor
and analyte being detected.
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Figure 1.1 Elements of a typical biosensor (Greishaber et al., 2008).
Biosensors can be classified in a broad sense based on the type of recognition event
that occurs. The two classifications are bioaffinity devices and biocatalytic devices.
Bioaffinity devices involve selective binding of a target analyte to a surface-immobilized
ligand coupler, such as an antibody (Murugaiyan et al., 2012). This classification can be
further divided into subclasses depending on the particular binding mechanism, such as
immunosensors, DNA biosensors, and cell biosensors (Liang et al., 2016). In comparison,
biocatalytic devices involve the utilization of an enzyme for catalyzing an anticipated
bioreaction. Because of this, enzymatic biosensors are the most common example of
biocatalytic devices (Borisov and Wolfbeis, 2008). A commonly known and frequently
used example of this is diabetes sensor strips.
Biosensors can also be classified based on the transduction mechanism, such as
electrochemical sensors and optical sensors. The literature review in Chapter 2 provides
details and examples of biosensors based on transducer classification. A summary is

2

provided in Table 1.1 of the function, advantages, and disadvantages of the different types
of sensors that will be discussed in more detail later.
Sensor Type
(transducer
classification)

Transducer
Function

Advantages

Disadvantages

converts chemical
signal into an
electronic signal

simplicity, low cost,
rapid results,
reproducibility,
exceptional detection
limits, miniaturization
capability

low sensitivity, low
specificity

Optical

converts light
rays into an
electronic signal

miniaturization
capability, multi-analyte
detection,
high sensitivity, high
specificity, rapid results,
doesn’t require molecule
labeling

ambient light
interference,
expensive, delicate,
complex to operate

Mechanical

converts mass or
position change
into an electronic
signal

rapid results, high
sensitivity, efficient with
limited sample
processing

not easily
reproduced

dependent on type
of sensor chip

small volume of
concentrations, quicker
diagnostics through the
manipulation of the
sensor geometry, highly
sensitive real-time
measurements, wide
range of designs and
techniques

undesirable
adsorption of nonspecific molecules,
solution
interference

Electrochemical

Biosensors
on-a-chip
(microfluidic &
chip
combination)

Table 1.1 Summary of the function, advantages, and disadvantages of the types of
biosensors discussed in Chapter 2.

Several characteristics can be used to compare the relative performance of different
types of biosensors. One characteristic is response time, that is, how fast a change in the
environment produces a change in signal. To have an ideal performance, changes in the
3

environment should produce a fast change in the resulting signal. Another important
characteristic is the limit of detection (LOD), which provides the lowest concentration of
an analyte that can be definitively detected. Lastly, selectivity and sensitivity are two of
the most common and important characteristics to evaluate. Selectivity measures whether
the sensor is responding only to the analyte being measured with no interference.
Sensitivity evaluates a change in detection based on a change in concentration (Catherino,
2006).
One aspect of biosensor function that seems to be scarcely studied and included in
experimental design and testing is the role of reaction kinetics and mass transport in
biosensing. Different analytes possess different reaction kinetics and mass transport
properties that play a role in their transport to and interaction with the biosensor surface.
The limit of detection, an important response feature as explained above, is often
determined by the mass transport of an analyte to the surface of the biosensor (Jin et al.,
2019). Mass transport can be governed by diffusion, convection, electromigration, or a
combination of these. Understanding what mass transport process is occurring can help
with biosensor optimization. In a study done by Anandan et al. (2007), the impact of
reaction kinetics and mass transport on glucose sensing electrodes integrated with
nanopillars was investigated. They found that for functionalized nanopillar array electrodes
(NAEs), or electrodes containing arrays of pillar shaped nanostructures with diameters
measuring on the nanoscale, an increased current response resulted due to the successful
mass transport that was aided by the low reaction rate constant of glucose. Their study
echoed the need for sensor optimization to accommodate the specific reaction kinetics and
mass transport properties of the analyte being used.
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Biosensors provide a wide range of applications in both the clinical and research
fields, including biomarker detection and analysis, drug discovery, in-situ monitoring and
diagnostics. However, there are ongoing challenges facing biosensing, which include but
are not limited to low sensitivity, poor specificity and proneness to fouling (Anandan et al.,
2007). Continued research into the advancement and improvement of biosensor design and
techniques of use is critical for medical advancement.

1.2

Objectives
Currently, there is an urgent need for rapid, specific, and reliable detection and

monitoring systems in both the research and clinical fields. Biosensors are well equipped
to fit this need and can be used in a multitude of different ways, either as a stand-alone
method or combined with other sensor platforms, imaging modalities or analysis
techniques. The use of biosensors is not a new concept, however, many improvements still
need to be made. Hence, continual research is being performed to improve biosensors and
their ability for in-situ monitoring and diagnostics.
Based on this need and the promising potential of biosensors used for biomarker
detection, the overall focus of this research is to develop an in-situ technique to measure
multiple biomarkers in vitro. More specifically, the objective of this research is to develop
a practical and cost-effective means to detect biomarkers in-situ, including glucose,
cholesterol, and oxygen.
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1.3

Structure of Thesis
Chapter 1: Introduction. Provides background information and an overview of

biosensors, including the elements of their construction and the testing characteristics.
Describes the objectives of this thesis and outlines the structure of this thesis.
Chapter 2: Literature Review. Provides a survey of the relevant literature focused on
the mechanism and applications of different types of biosensors, mainly electrochemical
biosensors, as well as other types of biosensors. Unmet needs within the field are also
explored.
Chapter 3: Glucose Detection Biosensor. Provides details on the materials, sensor
biofunctionalization methods, and detection mechanism, as well as discusses the results for
the glucose detection biosensor.
Chapter 4: Cholesterol Detection Biosensor. Provides details on the materials, sensor
biofunctionalization methods, and detection mechanism, as well as discusses the results for
the cholesterol detection biosensor.
Chapter 5: Oxygen Detection Biosensor. Provides details on the materials, sensor
biofunctionalization methods, and detection mechanism, as well as discusses the results for
the oxygen detection biosensor.
Chapter 6: Conclusion and Future Work. Provides a summary of the major outcomes
of this thesis and discusses future research work.
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CHAPTER 2.
2.1

LITERATURE REVIEW

Electrochemical Biosensors
Electrochemical biosensors are a method of sensing that commonly utilizes a three-

electrode system consisting of a reference electrode, a working electrode, and a counter
electrode. Some designs use only a two-electrode system, consisting of a reference and
working electrode, but it is less common. The reference electrode is usually made from
silver-silver chloride (Ag/AgCl) or is a saturated calomel electrode (SCE) and maintains a
stable potential by remaining a constant potential drop across the electrode-liquid interface.
Ag/AgCl and SCE reference electrodes are able to maintain a constant and known potential
because they are composed of a fixed concentration of chloride. The working electrode
functions as the site of the primary half-cell reaction and the counter electrode as the site
of companion half-cell reaction to facilitate continuing flow of electrons to maintain an
electrochemical reaction. This type of sensors provides an attractive design since there is a
direct transduction of a biological reaction into electrical signal (Figure 2.1).

Figure 2.1 Schematic of an electrochemical biosensor (Hernandez-Vargas et al., 2018).
(https://creativecommons.org/licenses/by/4.0/legalcode) (no changes made)
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Electrochemical biosensors supply many desirable advantages, such as simplicity,
low cost, rapid results, reproducibility, exceptional detection limits and miniaturization
capability. They are also advantageous due to their low power consumption and
compatibility with microfabrication technologies. However, there are some disadvantages
that allude to more research being performed and design modifications being made. These
undesirable properties include low sensitivity and low specificity. In complex biological
samples, issues arise with detection accuracy and the inability to distinguish from
background material in the sample (Grieshaber et al., 2008, Gangadharan et al., 2011). In
order to be successful and useful in a clinical setting, sensors need high sensitivity and
specificity in the human media being tested.
This type of sensor requires biomolecule immobilization techniques that each come
with advantages and disadvantages, with the chosen immobilization technique depending
on the design and intended use of the sensor. One technique is physical adsorption to the
surface. This method is reversible and involves the biomolecule being attached or
physically adsorbed to the material surface. This is desirable due to its simplicity and the
absence of harsh chemicals. However, this method is not considered reliable or
reproducible and can result in undesirable leaching during storage. Another technique used
is cross-linking reagents. This method is irreversible and involves using crosslinkers to
create strong covalent bonds that anchor biomolecules to the surface. This method can
result in stabilized proteins, which can lead to higher stability, but this method can also
cause loss of activity. Entrapment within a polymer or gel is another technique that is used.
Entrapment is an irreversible method that involves an enzyme held in place by a polymeric
gel structure. Substrates and other products are then allowed to traverse. This technique is
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convenient, gentle, and the degree of cross-linking can be controlled, which can minimize
undesirable leaching. Covalent attachment, an irreversible technique that involves
chemical coupling of biomolecules, has an advantage in that it is pH, temperature and ionic
strength resistant. Lastly, utilizing biomolecular interactions, known as affinity binding, is
a reversible technique that relies on a particular biochemical reaction. This method is
beneficial because the properties of the reaction can create a detectable response
(Catherino, 2006, Asal et al., 2018). Figure 2.2 provides an illustration of the
immobilization methods discussed.

Figure 2.2 Schematic of biomolecule immobilization techniques (Rodriguez et al., 2015).
(https://creativecommons.org/licenses/by/3.0/legalcode) (no changes made)

Kim et al. (2019) has recently conducted research on creating an electrochemical
biosensor that is both stretchable and disposable. Previous studies have been done on
stretchable, electrochemical biosensors for detecting ions, uric acid, and glucose, but no
studies have been conducted on detecting specific protein biomarkers. In this study, a
sensor was created that could detect low concentrations of tumor necrosis factor alpha
9

(TNF-𝛼), which is an inflammation biomarker. TNF-𝛼-activated signal transduction
pathways play a key role in vascular dysfunction, hypertension and atherosclerosis
(Urschel and Cicha, 2015). Therefore, this biomarker may be important to monitor with
respect to cardiovascular disease (CVD). There proved to be durability and high stability
after static and cyclic stretching, suggesting that this design condition could be further
applied to wearable sensors.
Electrochemical biosensors have been utilized in the detection of an array of
biomarkers, both lipidic and amphiphilic. The most common and successfully
commercialized use is for the detection of glucose, in the form of glucose monitors used
primarily by individuals with diabetes (Kubicek-Sutherland et al., 2017). Further, when
considering cardiac biomarkers in particular, electrochemical biosensors have been used to
detect cardiac troponin I or T (cTnI/T), myoglobin, C-reactive protein (CRP), Lipoproteinassociated phospholipase A, IL-6, LDL and MPO. Out of these, one of the most
noteworthy, presented by Qureshi et al. (2012), is a miniaturized point-of-care sensor used
for detecting myoglobin, with the ability to detect a concentration of 100 ng/ml. This sensor
functions through the use of an antibody layer that is immobilized on a planar gold
electrode. Cardiac enzyme is seized by this layer and sensed through impedimetric sensing.
CRP is a cardiac biomarker known to be a sensitive indication of infection,
inflammation and cardiac risk. Current CRP testing methods used in a clinical setting, such
as enzyme-linked immunosorbent assay (ELISA), are time consuming, inaccurate or don’t
produce an acceptable sensitivity. Due to this, Bryan et al. (2013) have developed and
optimized an electrochemical, label free biosensor that is reusable and provides consistent
detection of CRP in dilute or whole blood serum. Other sensor types developed for CRP
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detection were researched (surface plasmon resonance, piezoelectric microcantilevers,
microfluidics, etc.) and electrochemical methods proved to be most advantageous for low
cost, sensitivity and flexibility.
Electrochemical biosensors can be further classified based on the type of
measurement that is taken. More specifically, these biosensors can be classified as
amperometric, potentiometric, impedimetric, and conductometric. These subclasses of
electrochemical biosensors will be discussed in further detail next.

2.1.1

Amperometric
Amperometric biosensors are a subclass of the electrochemical biosensor and

involve the transfer (either loss or gain) of electrons. This subclass functions by applying
a potential, or voltage, to the system and measuring the current response that arises from
electron transfer on the working electrode that results from the biochemical reaction that
takes place, and the products that are oxidized or reduced during this reaction (Chaubey
and Malhotra, 2002). For enzyme sensors, reactions involving a single analyte, or substrate,
can be written in a general form:
𝐸 + 𝑆 ⇌ 𝐸𝑆 ⟶ 𝐸 + 𝑃

(1)

where E is the enzyme, S is the substrate and P is the product. The intermediate complex
ES breaks down into products P and liberates the enzyme (Wang, 2000). For example, a
common final reaction that is monitored amperometrically is the liberation of hydrogen
peroxide, denoted as:
𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑑𝑒

𝐻2 𝑂2 →

𝑂2 + 2𝐻+ + 2𝑒 −
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(2)

This enzymatic activity determines the sensor response in the form of the resulting
electrochemical current. In the above example, an oxidation reaction is occurring, denoted
by the loss of electrons. In general, the loss or gain of electrons, depending on if an
oxidation or reduction process is occurring, leads to the current measurement. The more
efficient the electron transfer, the larger the current response. The peak current value
measured over a linear potential range is directly proportional to the bulk concentration of
the analyte (Grieshaber et al., 2008). As discussed previously, two half-cell reactions occur
on the working and counter electrode. The electrochemical event occurs at the working
electrode and produces either a reduction or oxidation. If reduction occurs at the working
electrode, oxidation occurs at the counter electrode. Due to this, the counter electrode
should be composed to be as inert as possible (Elgrishi et al., 2018). The composition of
the transducer varies based on the type of sensor being used and the particular reaction
taking place. Because of the need for an inert material, amperometric biosensors use metal
or carbon electrodes, or chemically modified electrodes (CMEs) as the transducer element
(Catherino, 2006).
Reactions that occur can be mediated or non-mediated, as shown in Figure 2.3.
Mediators are synthetic electron transferring vehicles that can freely partake in the redox
reaction with the biological component. This assists in rapid electron transfer. There are
different types of mediators including ferrocene, conducting salts, quinones, and many
others (Chaubey and Malhotra, 2002). Mediators may improve a sensors sensitivity and
specificity, as well as contribute to a faster response time. Also, mediated enzyme
electrodes have lower electrode potentials and therefore are less receptive to interfering
elements.
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Figure 2.3 Schematic of mediated and unmediated electron transfer (Chaubey and
Malhotra, 2002). Reprinted from Biosensors and Bioelectronics, 17, A. Chaubey and
B.D. Malhotra, Mediated Biosensors (Review), 441-456, 2002, with permission from
Elsevier.

The behavior of amperometric biosensors can be visualized mathematically by
examining the Cottrell equation:
𝑖(𝑡) =

𝑛𝐹𝐴𝐶𝐷1/2
𝜋 1/2 𝑡1/2

(3)

where 𝑛 is the stoichiometric number of electrons involved in the reaction, 𝐹 is Faraday’s
constant, 𝐴 is the area of the electrode (cm2), 𝐶 is the concentration of the electroactive
species (mol/cm3), 𝐷 is the diffusion constant for the electroactive species (cm2/s) and t is
time. This equation shows the change in current with respect to time and it can be seen that
the current is proportional to the square root of the diffusion rate. The diffusion constant
can be found by rearranging the equation and determining the number of electrons using
amperometric techniques. Current depends on the rate at which the analyte diffuses to the
electrode, so current is diffusion controlled. This behavior can be visualized graphically
through the Cottrell diffusion curve, shown in Figure 2.4.
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Figure 2.4 The plot on the left shows that current is inversely proportional to the square
root of t. The plot on the right shows the corresponding concentration profile. (Trinh,
2011). (https://creativecommons.org/licenses/by-nc-sa/3.0/) (no changes made)

Amperometric biosensors can be used to measure cholesterol concentration in the
blood. This is important due to the negative relation between cholesterol content,
atherosclerosis and CVD. Enzymatic amperometric biosensors have laid the foundation
and have become the most commonly used approach for cholesterol biosensors. This
approach involves the immobilization of an enzyme, most commonly cholesterol oxidase,
ChOx, on the electrode surface. Electron transfer between the electrode and the enzyme
occurs due to a redox reaction between the enzyme and cholesterol. Cholesterol is
catalyzed by ChOx and leads to O2 consumption and H2O2 production. The O2
consumption and H2O2 production that occurs is not measured directly. Instead, as
described by the Cottrell equation, the current that is measured expresses the rate of
electron transfer occurring in the reaction. Further, since the analyte concentration that is
present is proportional to the current outputted, the cholesterol concentration is able to be
measured (Saxena and Das, 2016).
Although these cholesterol sensors have their advantages in their in-situ monitoring
capabilities and their easiness to be miniaturized, there are a few disadvantages, such as a
lack of sensitivity and stability. A common strategy to counter the reduction in current
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signal that occurs with the reduction in electrode size is to increase the surface area through
the use of nanostructures (Gangadharan et al., 2011). Saxena and Das (2016) presents the
addition of nanomaterials to their design in order to combat these disadvantages. Different
types of nanoparticles (metal, metal oxide, carbon nanotubes) have been used to improve
the amperometric cholesterol biosensor (Figure 2.5).

Figure 2.5 Facilitation of electron transfer between the electrode and the ChOx redox
center by AuNP's (Saxena and Das, 2016). Reprinted from Biosensors and
Bioelectronics, 75, U. Saxena and A.B. Das, Nanomaterials Towards Fabrication of
Cholesterol Biosensors: Key Roles and Design Approaches, 196-205, 2016, with
permission from Elsevier.

Carbon nanotubes (CNTs) are most commonly used for cholesterol biosensors
because of their strong electrocatalytic properties for H2O2. Nanomaterial incorporation in
different ways has shown to increase both the sensitivity and stability of the cholesterol
sensor specifically (Saxena and Das, 2016).
Chauhan and Pundir (2014) presented an amperometric biosensor for the detection
of acetylcholine. It is believed that Alzheimer’s disease can result, in part, from
dysfunctional regulation of the neurotransmitter acetylcholine. This biosensor was created
by co-immobilizing acetylcholinesterase and choline oxidase onto nanocomposite of
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chitosan (CHIT)/gold-coated ferric oxide nanoparticles (Fe@AuNPs) deposited onto a Au
working electrode. The reference electrode was composed of Ag/AgCl and the counter
electrode was a platinum wire connected through the potentiostat. The H 2O2 that resulted
from the oxidation of choline by immobilized choline oxidase was measured
electrochemically using cyclic voltammetry. Measurement of acetylcholine was also
performed in fresh plasma samples from both healthy persons and persons suffering from
Alzheimer’s disease. This sensor showed to have high specificity, a fast response time of
3 seconds, and a low detection limit of 0.005 M. It provided accurate results when
compared with the current method of detection, high performance liquid chromatography
(HPLC), graphically seen in Figure 2.6.

Figure 2.6 Correlation between acetylcholine values determined by the discussed
biosensor (x-axis) and by standard HPLC method (y-axis) (Chauhan and Pundir, 2014).
Reprinted from Biosensors and Bioelectronics, 61, N. Chauhan and C.S. Pundir,
Amperometric Determination of Acetylcholine – A Neurotransmitter, by Chitosan/GoldCoated Ferric Oxide Nanoparticles Modified Gold Electrode, 1-8, 2014, with permission
from Elsevier.
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2.1.2

Potentiometric
A second subclass of the electrochemical biosensor is the potentiometric biosensor,

which functions by measuring the potential at the working electrode with respect to the
reference electrode under equilibrium conditions. The accumulation of charge is measured
with zero or no significant current flowing between the two electrodes. The change in
voltage results from the selective binding mechanism that occurs at the electrode surface
(Chaubey and Malhotra, 2002). The relationship between potential and concentration is
governed by the Nernst equation:
0
𝐸𝑐𝑒𝑙𝑙 = 𝐸𝑐𝑒𝑙𝑙
−

𝑅𝑇
ln(𝑄)
𝑛𝐹

(4)

where 𝐸𝑐𝑒𝑙𝑙 is the observed cell potential at zero current or the electromotive force (EMF)
0
of the cell, 𝐸𝑐𝑒𝑙𝑙
is a constant potential contribution to the cell, 𝑅 is the universal gas

constant, 𝑇 is absolute temperature in degrees Kelvin, 𝑛 is the charge number of the
electrode reaction, 𝐹 is the Faraday constant, and 𝑄 is the ratio of ion concentration at the
anode to ion concentration at the cathode (Grieshaber et al., 2008). Transducer types for
potentiometric biosensors include ion-selective electrodes (ISE), glass electrodes, gas
electrodes, metal, and metal hybrids (Catherino, 2006).
Potentiometric biosensors can be used to measure cholesterol, a lipid antigen. Lipid
antigens are detected using lipid films (Kubicek-Sutherland et al., 2017). One such
successful example is a potentiometric cholesterol biosensor created with graphene
consisting of polymeric lipid membranes. This biosensor was tested in real blood serum
samples and proved to have a lower detection limit than previously reported devices,
making it useful for clinical analysis and practical applications. The resulting EMF data is
shown in Figure 2.7. This figure also shows how the stability and reusability of the
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biosensor was tested and presented promising results. However, it is noted that these
experiments were conducted in solution with a pH value of 7.0, since it was determined
this provides the optimal response from the biosensor (Nikoleli et al., 2013). The normal
pH range for human blood is about 7.35 to 7.45 (Lewis, 2020). It would be important to
perform further testing and note the effect of this increased pH on the biosensor
performance.

Figure 2.7 Calibration Curves for three consecutive experiments on single biosensor
(Nikoleli et al., 2013). (https://creativecommons.org/licenses/by-nc-nd/3.0/legalcode) (no
changes made)
2.1.3

Impedimetric
A third subclass of the electrochemical biosensor is the impedimetric biosensor,

which involves a change in electron transfer behavior across the electrode-liquid interface
resulting from a change in impedance consisting of resistance and capacitance occurring at
the working electrode as selective binding occurs. Impedimetric biosensors can be
visualized through circuit models, as shown by the Randles circuit model in Figure 2.8.
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Figure 2.8 Common Randles circuit model for impedimetric measurements (Ahmed et
al., 2014). Republished with permission of Clinical Microbiology Reviews, form
Biosensors for Whole-Cell Bacterial Detection, A. Ahmed, J.V. Rushworth, N.A. Hirst,
P.A. Millner, 27, 3, 2014; permission conveyed through Copyright Clearance Center, Inc.
𝑅𝑠 is the solution resistance, 𝐶𝑑𝑙 is the double layer capacitance, 𝑅𝑐𝑡 is the charge
transfer resistance and W is the Warburg impedance, which is only observed in some
operations at a low frequency (Ahmed et al., 2014). Mathematically, impedance for a
simplified Randles circuit that doesn’t include Warburg impedance can be calculated by
using the following equation:
𝑍 = 𝑅𝑠 +

𝑅𝑐𝑡
1 + 𝑗𝜔𝑅𝑐𝑡 𝐶𝑑𝑙

(5)

This relationship is shown graphically in Figure 2.9 A. Rs represents the solution resistance,

Rct represents the charge transfer resistance, and Cdl represents the double-layer
capacitance. This provides the impedance response curve shown, with the semicircular
shape indicating electron transfer blockage across an electrode/electrolyte boundary
(Anandan et al., 2009). R, the resistance, termed the “real component of impedance”, is
located on the x-axis, and C, the capacitance, termed the “imaginary component of
impedance” is located on the y-axis. It is shown that as the diameter of the semi-circle
changes, the impedance changes. Nyquist plots showing both a semicircle and linear region
indicate a combination of kinetics-controlled and diffusion-controlled electrode processes.
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For example, if at low frequency the linear region of the Nyquist plot is absent, it would be
inferred that after various molecules are adsorbed, the process is kinetics-controlled and is
no longer diffusion-controlled (Lee et al., 2008). A kinetics-controlled reaction is a reaction
limited by the rate of electron transfer, whereas a diffusion-controlled reaction is a reaction
in which the rate is dependent on the diffusion of electroactive species from a region of
high concentration to a region of low concentration, or the mass transport of the species to
the surface of the electrode.
In practice, measuring impedance is done by applying a voltage and measuring the
resulting current and phase shift. The impedance is given by this current-voltage ratio, and
can either increase or decrease depending on the analyte being studied (Rushworth et al.,
2013). For example, if a voltage is applied, then the voltage (V) and resulting current (I)
would take the form:
𝑉 = 𝑉𝐷𝐶 + 𝑉𝐴𝐶 sin(𝜔𝑡) 𝑎𝑛𝑑𝐼 = 𝐼𝐷𝐶 + 𝐼𝐴𝐶 sin(𝜔𝑡 − 𝜑)

(6)

And the impedance would have a magnitude of:
𝑍(𝜔) =
and phase 𝜑 (Daniels and Pourmand, 2007).
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𝑉𝐴𝐶
𝐼𝐴𝐶

(7)

B

A

Figure 2.9 Nyquist plot containing features of Randles circuit (A) and changes in
impedance resulting from analyte-surface interactions (B) (Ahmed et al., 2014).
Republished with permission of Clinical Microbiology Reviews, form Biosensors for
Whole-Cell Bacterial Detection, A. Ahmed, J.V. Rushworth, N.A. Hirst, P.A. Millner,
27, 3, 2014; permission conveyed through Copyright Clearance Center, Inc.

The response curve that results from impedance measurement provides the
relationship between the output variable of the sensor and the concentration of the target
analyte (Daniels and Pourmand, 2007). Since impedimetric biosensors present a change in
capacitance and electron transfer resistance across the working electrode as a result of
analyte-bioreceptor interaction, it follows that as analyte binding increases the impedance
changes. As shown in Figure 2.9 B, the impedance changes that result from these
interactions are proportional to the analyte concentration present (Ahmed et al., 2014).
In a review by Bahadir and Sezginturk (2016), it is stated that there are two main
recognition mechanisms of impedimetric sensors that are studied. These types are
impedimetric immunosensors, which involve antibodies and antigens binding causing
electron transfer and a change in resistance, and impedimetric aptasensors, which involve
the binding of target sequences, DNA damages, or conformational changes that result in
impedance changes. Both recognition mechanisms of impedimetric sensors have
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advantages, such as reproducibility and high specificity. However, it is important to note
that higher specificity, better stabilization and longer shelf left has been reported for the
use of aptamers compared to antibodies.
This type of biosensor has been used for the detection of important Alzheimer’s
disease biomarkers. For example, an Electrochemical impendence spectroscopy (EIS)
biosensor was created consisting of graphene oxide/gold nanoparticles (GNPs) and a
hydrogel electrode with the immobilization of cellular prion protein (PrP C) peptide probe
on the GNPs to target soluble biomarker amyloid-beta oligomers (A𝛽O) present in blood
or cerebral spinal fluid (Sun et al. 2018). This sensor proved to be highly specific and
sensitive for the detection of A𝛽O, with a detection limit as low as 0.1 pM. The sensor was
also able to distinguish between A𝛽O and amyloid-beta monomers or fibrils.
Rushworth et al. (2014) have presented a label-free electrical impedimetric
biosensor that also detects A𝛽O in relation to Alzheimer’s disease. Their design is similar
to the previously mentioned design in that it utilizes PrPC, however, instead of using
hydrogel for attachment a biotin/NeutrAvidin bridge was used. EIS was used for analysis,
along with cyclic voltammetry and scanning electron microscopy. This biosensor proved
to be specific for detecting A𝛽O and provided a detection limit of ~0.5pM, which is higher
than the previously discussed design by Sun et al. (2018).
2.1.4

Conductometric
A fourth subclass of the electrochemical biosensor is the conductometric biosensor,

which measures conductance changes between two electrodes as a result of the biochemical
reaction that occurs (Chaubey and Malhotra, 2002). Conductometric biosensors are
sometimes noted as a subclass of the impedimetric biosensor since conductance is the
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inverse value of resistance (Pohanka and Skladal, 2008). Based on this relationship,
conductance can be derived from Ohm’s law (𝑉 = 𝐼 ∗ 𝑅), giving conductance as:
𝐺=

𝐼
𝑉

(8)

where V is voltage, I is current, R is resistance and G is conductance. For conductometric
sensing, a voltage is applied to the system and a resulting current is measured. When
voltage is applied, a biochemical reaction occurs that changes the concentration of the ionic
species. This change in ionic concentration leads to a change in current flow. By examining
equation ( 8 ), it can be seen that a change in current will result in a change in conductance.
An example of this measurement is shown in Figure 2.10.
This type of biosensor is commonly used to study enzymatic reactions (Grieshaber
et al., 2008). Metal electrodes are the most commonly used transducer type for this type of
biosensor (Catherino, 2006). Clinical samples have varying and potentially complex ionic
backgrounds and require the measurement of small conductance changes in media of high
ionic strength. This presents a limitation for conductometric biosensors and restricts the
applicability for this form of biosensing in real clinical applications (Grieshaber et al.,
2008).
A single polyaniline (PANI) nanowire biosensor with an integrated microfluidic
channel has been developed that can successfully detect myoglobin (Myo), cardiac
troponin I (cTnI), creatine kinase-MB (CK-MB), and b-type natriuretic peptide (BNP),
which are critical biomarkers used in diagnosing CVD (Lee et al., 2012). In this design,
conductance measurement was chosen due to its ability to produce a quick response and
function without the need for a reference electrode. Microfluidic channels were integrated
for more precise sensing, to slow flow of the solution through only the active portion of
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the PANI nanowire, for reliable sensing and for overall system stability. Conductance
measurement detection results are shown in Figure 2.10.

Figure 2.10 (a) Detection of Myo (a: PBS, b: 100 ng/mL BSA, and c: 100 pg/mL Myo);
(b) Detection of cTnI (a: PBS, b: 10 ng/mL BSA, c: 5 fg/mL cTnI, d: 250 fg/mL cTnI, e:
20 pg/mL cTnI); (c) Detection of CK-MB (a: PBS, b: 10 mg/mL BSA, c: 150 fg/mL CKMB); (d) Detecion of BNP (a: PBS, b: 100 ng/mL BSA, c: 50 fg/mL BNP, and d: 1
pg/mL BNP) (Lee et al., 2012). (https://creativecommons.org/licenses/by/3.0/legalcode)
(no changes made)

Overall, this sensor design detects Myo, cTnI, CK-MB and BNP at low
concentration levels while maintaining very high sensitivity and specificity, and having
good reproducibility.

2.2

Other Biosensors

Although this thesis is focused on electrochemical biosensors, to complete the survey of
literature other types of sensors were examined and are discussed in the next sections.
These sensor types include optical, mechanical, and on-chip biosensors.

24

2.2.1

Optical Biosensors
Optical biosensors are sensors that measure the light emitted or absorbed as a result

of a biochemical reaction. Optical fibers or waveguides are used to guide the light wave to
appropriate detectors (Chaubey and Malhotra, 2002). A schematic of a basic optical
biosensor, including potential transducer elements, is shown in Figure 2.11. Different types
of optical biosensors include colorimetric, fluorescence, luminescence, surface plasma
resonance (SPR) and fiber optic. The specific theory and mechanism used to operate the
biosensor depends on the chosen transducer and intended function. A few specific types
will be described in more detail below.

Figure 2.11 Schematic of an optical biosensor (Long et al., 2013).
(https://creativecommons.org/licenses/by/3.0/legalcode) (no changes made)

Optical biosensors are advantageous due to their sensitivity, ability to produce rapid
results, high specificity, and the ability to produce quantitative and kinetic measurements
(Qureshi et al., 2012). Furthermore, optical biosensors do not require molecule labelling to
produce a higher accuracy and allow for in-situ monitoring. However, the sensors can be
delicate and costly, and familiarity of the theory of the experiment and of optics may be
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required by the user to obtain meaningful results (Ramsden, 1997). Further limitations that
have encouraged more research into creating a more robust optical sensor are
miniaturization difficulty, a lack of resolution, and issues with efficient use in turbid media.
Different forms of optical biosensors have been used to detect promising
biomarkers for the diagnosis and progression analysis of Alzheimer’s disease. One
example, by Song et al. (2018), uses a label-free optical nanosensor design to detect AD
biomarkers beta-amyloid (A𝛽42) and total tau (T-tau) in buffer and in CSF. Four
nanosensors were fabricated on a chip, with one sensor acting as a reference, one used to
detect A𝛽42, one used to detect T-tau, and the last to detect a mixture of A𝛽42 and T-tau.
When the specific biomarker binds to the corresponding antibody immobilized on the
sensing surface, a shift occurs in the reflected optical signal and this is monitored. This
sensor design proved to have important advantages such as high specificity and sensitivity,
great repeatability, low cost and ease of operation, making them a promising device for
point-of-care diagnostics. The detection limit was also low in buffer, with A𝛽42 detectable
at 7.8 pg/ml and T-tau detectable at 15.6 pg/ml.
Although there are many different subclasses of optical biosensors, two have been
chosen to be examined further: surface plasmon resonance (SPR) optical biosensors and
fiber optic SPR biosensors.

2.2.1.1 Surface Plasmon Resonance (SPR)
Surface plasmon resonance is a subset of optical biosensors that uses surface
plasma waves to examine biomolecular interactions occurring at the surface of the sensor.
Biomolecular recognition elements are immobilized on the surface. Analyte molecules
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bind to these, and the refractive index is increased, which changes the propagation constant
of the surface plasmon wave (SPW). A change is measured in one of the properties of the
light wave interacting with the SPW (Homola et al., 2002). The properties measured are
traditionally the wavelength, the incident angle or the intensity of the reflected light. The
change that occurs in the measured property provides a measurement of the target analyte
adsorbed (Hoa et al., 2007). The basics of the SPW vector (𝛽𝑆𝑃 ) is given by the following
equation:

𝛽𝑆𝑃 = 𝑅𝑒 {

2𝜋
𝜀𝑀 𝜀𝐷
}
√
𝜆 𝜀𝑀 + 𝜀𝐷

(9)

where 𝜆 is the wavelength of the incident light, 𝜀𝑀 is the value of the real part of the metal
dielectric constant, and 𝜀𝐷 is the value of the real part of the medium dielectric constant
(Prabowo et al., 2018).
In order for a light wave to couple to a SPW at a metal-dielectric interface, the
component of light’s wavevector that is parallel to the interface must match that of the
SPW. In most cases, the light’s wavevector needs to be enhanced to match the wavevector
of the SPW and to allow for excitation of the SPW (Homola et al., 2002). This excitation
can be done using different coupling methods such as grating coupling, waveguide
coupling, fiber optic coupling (Liang et al., 2016) and prism coupling (Figure 2.12)
(Homola et al., 2002).
SPR biosensing allows for both qualitative and quantitative measurement data, realtime measurements, and doesn’t require labeling. SPR biosensors can detect concentration
levels of an analyte from a complex sample, which is advantageous for clinical applications
(Hoa et al., 2007). However, for compatibility purposes the metal surface of the electrode
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has to be coated, and an analysis of the entire resonance curve is required, which is timeconsuming (Ramsden, 1997). An example of a resonance curve is shown in Figure 2.12.

Figure 2.12 (a) schematic of prism-coupled structure and (b) resonance shift in reflected
light spectrum (Hoa et al., 2007). Reprinted from Biosensors and Bioelectronics, 23, X.D.
Hoa, A.G. Kirk, and M. Tabrizian, Towards Integrated and Sensitive Surface Plasmon
Resonance Biosensors: A Review of Recent Progress, 151-160, 2007, with permission
from Elsevier.
Traditional prism-coupled SPR designs are the general basis for today’s
commercial systems of SPR biosensors and will be discussed in greater detail in this paper.
Advantages include simplicity, sensitivity and robustness. One main disadvantage is the
inability or difficulty of miniaturization. This has caused alternatives, such as optical fibers
and waveguide structures to be proposed and explored. There are also subsets of SPR
biosensors that result in different sensitivities. These are fiber-SPR, waveguide-SPR,
silicon-SPR, and multi-analyte SPR (Hoa et al., 2007).
To fully understand how coupling works, an example of a prism coupler will be
examined. The underlying principle includes conducting the excitation using transverse
magnetic ™ wave (𝑘) through a medium that has a higher refractive index than the
boundary dielectric medium. The resonance condition, or the point of intersection, can be
described by (Prabowo et al., 2018):
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𝑘𝑋 = 𝛽𝑆𝑃

( 10 )

2𝜋
2𝜋
𝜀𝑀 𝜀𝐷
∗ 𝑛𝑃 ∗ sin 𝜃 =
∗ 𝑅𝑒 {√
}
𝜆
𝜆
𝜀𝑀 + 𝜀𝐷

( 11 )

where 𝑛𝑃 is the prism material and 𝜃 is the incident angle. It follows then that the incident
angle can be calculated using the following equation:
𝜃 = sin−1 [(

1
𝜀𝑀 𝜀𝐷
) ∗ 𝑅𝑒 {√
}]
𝑛𝑃
𝜀𝑀 + 𝜀𝐷

( 12 )

It is shown in Figure 2.13 that the propagation constant of incident light can couple the
wavevector of SPW at the intersection point.

Figure 2.13 The relation between the dispersion of TM incident light coupling a SPW
(Prabowo et al., 2018). (https://creativecommons.org/licenses/by/4.0/legalcode) (no
changes made)

When performing an experiment using SPR, the shift in this incident angle is
observed and measured and represents the adsorption activity when plotted as a function
of time (Biosensing Instrument Inc., 2014). An example of results obtained from such an
experiment is shown graphically in Figure 2.14.
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SPR biosensors have been widely studied and used for detection of particular
cardiac biomarkers. These include metalloproteinase (MMP)-2, B-type natriuretic peptide
(BNP), cTnT, myoglobin, cTnl, TNF-a, and MPO. They have also been used for detecting
modified CRP (mCRP), which is an important indicator for assessing risk of developing
CVD (Qureshi et al., 2012). Hu et al. (2006) report on the creation of an SPR biosensor
that can accurately detect mCRP in real time. The detection of both pentamer C-reactive
protein (pCRP) and mCRP is analyzed in the study through the use of different monoclonal
antibodies (Mabs) immobilized on a protein G layer, and pCRP is used independently to
evaluate the detection level. Figure 2.14 shows the SPR responses, in the form of angle
shift over time, that resulted from the binding of Mab C8 with pCRP and mCRP, indicating
that Mab C8 reacts with both pCRP and mCRP.

Figure 2.14 SPR sensorgram trace of antibody-antigen interaction of Mab C8 against
pCRP and mCRP (Hu et al., 2006). Reprinted from Biosensors and Bioelectronics, 21,
W.P. Hu, H.-Y. Hsu, A. Chiou, K.Y. Tseng, H.-Y. Lin, G.L. Chang, and S.-J. Chen,
Immunodetection of Pentamer and Modified C-reactive Protein Using Surface Plasmon
Resonance Biosensing, 1631-1637, 2006, with permission from Elsevier.
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Based on the results, the biosensor has the ability to be used in clinical applications
for the detection of CRP at clinical concentrations. However, it is noted that when
compared with the high sensitivity CRP assay that has the lowest detection limit, this
biosensor does not perform better but does rival other assay methods, such as enzymelinked immunosorbent assay (ELISA).
SPR biosensors have also been studied and used for the detection of particular
Alzheimer’s disease biomarkers. One example is a multichannel SPR biosensor for the
detection of 17beta-hydroxysteroid dehydrogenase type 10 (17𝛽-HSD10), a biomarker that
is a possible target for Alzheimer’s disease diagnostics (Hegnerova et al., 2009). This
sensor uses a self-assembled monolayer for the immobilization of biorecognition
components against 17𝛽-HSD10. The results show the sensor can detect 17𝛽-HSD10
enzyme at ng/ml levels in artificial cerebrospinal fluid. Further studies will need to be
performed to test the sensors detection capabilities in human cerebrospinal fluid.

2.2.1.2 Fiber Optic SPR Sensors
Another subclass of optical biosensors is fiber optic SPR biosensors. This subclass
of optic sensor has gained popularity recently and has been investigated more extensively
due to its ability to effectively handle measurement situations that other, more conventional
sensors cannot handle, such as sensing in low sample volumes and portability. These
biosensors involve the binding of a target analyte to the biological recognition component,
which causes variation in the refractive index of the absorbed layers at the metal surface.
All types of fiber optic SPR biosensors, which includes immunoassay, DNA, enzyme and
living cell, rely on this mechanism (Liang et al., 2016).
31

In contrast to SPR biosensors, fiber optic SPR biosensors incorporate optical fiber
that consists of a core that can replace components, such as a prism, in the sensing system.
A schematic of a typical fiber optic SPR sensor is shown in Figure 2.15.

Figure 2.15 Schematic of a typical fiber optic SPR sensor with straight probe design
(Gupta et al., 2016). (https://creativecommons.org/licenses/by/4.0/legalcode) (no changes
made)

Although different, a fiber optic SPR biosensor follows the same basic principles
involving the fundamentals of SPW and the SPR biosensor design that was discussed
previously. In the case of a fiber optic SPR biosensor, the prism is replaced by the core of
an optical fiber. Total internal reflection is the method of light transmission in optical
fibers. The total internal reflection (TIR) of the guided ray at the core-cladding interface
lends to the light guidance of the evanescent wave in the optical fiber (Gupta and Verma,
2009). The refractive index of the core (𝑛1) must be larger than the refractive index of the
cladding (𝑛2 ), and the angle of incidence has to be larger than the critical angle for total
internal reflection and propagation of light through the fiber to occur. The critical angle
can be calculated mathematically by Snell’s law (Marazuela and Moreno-Bondi, 2002):
𝜃𝐶 = sin−1 𝑛2 /𝑛1

32

( 13 )

These sensors are constructed by removing the cladding of the fiber and revealing
the bare core of the sensing section. A metal coating and dielectric region is then used to
coat the section. Guided rays are propelled into the fiber and produce evanescent waves,
which stimulate surface plasmons at the metal-dielectric boundary (Gupta et al., 2016).
Transmitted light is detected at the output side of the optical fiber at the resonance
wavelength.
Measurement of resonance wavelength allows the examination of the interaction
between the analyte and the sensing surface (Kant and Gupta, 2018). Obtaining
experimental results involves analyzing SPR response curves that contain light intensity
data at given wavelengths for analyte concentrations. The resonance wavelengths (dip in
the curve) can then be determined and plotted against analyte concentration to obtain the
calibration curve (Gupta et al., 2016, Kant and Gupta, 2018). An example of these results
is shown in Figure 2.16.
These sensors are ideal for their simple optical setup that includes no
electromagnetic interference. Other advantages include the capability for remote, in-situ
and label-free sensing, low cost, high sensitivity, miniaturization ability, portability and
compactness. Similarly to SPR optical biosensing, fiber optic SPR has shallow penetration
depth, although this limitation is reduced with fiber optic SPR compared with SPR. These
sensors have currently been used for monitoring artificially buffered samples and haven’t
been used for real clinical samples and medical diagnostics yet (Liang et al., 2016).
Similarly to SPR biosensors, fiber optic SPR biosensors have also been used to
detect cardiac biomarkers. The cardiac biomarkers detected are BNP, cTnl, Mg, CRP,
nerve growth factor (NGF), and IL-6 (Qureshi et al., 2012). Tang et al. (2007) developed
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and tested a fiber optic immunobiosensor for point-of-care analysis of human plasma NGF.
NGF is a biomarker that is indicative of cardiac arrhythmia and has been used for CVD
diagnosis and projection. Identical tests were performed with both the biosensor and the
standardly used and accepted ELISA method to provide a comparison between the two
modalities. The fiber optic immunobiosensor had a faster response time than ELISA and
was able to quickly quantify (within 5 minutes) physiological concentrations of NGF in
buffer and human blood plasma samples. The data accuracy was comparable between the
two methods, making the sensor a promising point-of-care option that can be utilized for
detection of NGF and other clinically noteworthy cardiac biomarkers.
It is hypothesized that a substantial drop in the synthesis of acetylcholine is linked
to the cause of Alzheimer’s disease. Based on this, a fiber optic SPR based acetylcholine
biosensor was created to aid in the diagnosis of Alzheimer’s disease (Kant and Gupta,
2018). This sensor functions by creating a sensing surface that is comprised of tantalum
(v) oxide (Ta2O5) nanoflakes functionalized with acetylcholinesterase enzyme. This design
proved to be advantageous in many aspects, such as compactness, ease of use, cost
efficiency, and ability for remote sensing. SPR response curves were generated for
different concentrations of acetylcholine, shown in Figure 2.16 (left). The resonance
wavelength values were determined from these curves and plotted against acetylcholine
concentration to form the calibration curve, shown in Figure 2.16 (right).
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Figure 2.16 SPR response curves for range of acetylcholine concentrations (left) and
calibration curve showing resonance wavelength variation vs. acetylcholine concentration
(right) (Kant and Gupta, 2018). © 2018 IEEE

This sensor was also optimized for high sensitivity and high selectivity towards
acetylcholine. It presents a LOD value of 38 nM, which is reported to outperform other
detection techniques for acetylcholine. This experimental design was performed in a lab,
and although the pH was set to mimic blood pH value, further testing may need to be
performed to test the viability in true clinical applications.
2.2.2

Mechanical Biosensors
Mechanical biosensors provide a method of measurement that is rapid and can

produce sensitive measurements, while requiring only limited sample processing.
However, although mechanical biosensors are rapid, they are not easily reproduced. There
are two main techniques used for mechanical biosensors: quartz crystal microbalances
(QCM) and cantilever (Figure 2.17).
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Figure 2.17 (a) schematic of a QCM chip (http://biosensingusa.com/technicalnotes/technical-note-103-surface-plasmon-resonance-v-quartz-crystal-microbalance/) (b)
schematic of a cantilever configuration (Kubicek-Sutherland et al., 2017).
(https://creativecommons.org/licenses/by/4.0/legalcode) (no changes made)

QCM detects resonance frequency changes on the surface due to mass increase
from analyte binding. Cantilever technique involves a receptor-functionalized
microcantilever that is sensitive to the specific biomolecule. Mechanical bending is
measured upon binding of this microcantilever with the target molecule (KubicekSutherland et al., 2017).
A QCM consists of a quartz crystal, a gold electrode, and connecting metal wires.
The quartz crystal is placed between two electrodes, creating an electric field that produces
a mechanical oscillation in the crystal. The frequency change (∆𝑓) that occurs due to
change in mass (∆𝑚) is governed by the following Sauerbrey equation:
∆𝑓 =

−2∆𝑚𝑛𝑓02
𝐴√𝜇𝜌

( 14 )

where 𝑛is the overtone number, 𝑓0 is the base resonant frequency of the crystal before the
mass change, 𝐴 is the area, 𝜇 is the shear modulus of quartz, and 𝜌 is the density of quartz.
From this equation it can be seen that an increase in mass corresponds to a decrease in
frequency (Wang, 2000).
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For use in the cantilever method, these small cantilevers can be surface-stress
sensors or dynamic-mode sensors (Arlett et al., 2007). The surface-stress mechanical
biosensor measures the quasistatic deflection caused by the binding of biomolecules to
functional groups located on the surface of the sensor. One way that the deflection can be
measured is by the reflection of a laser beam off the cantilever. The equation that governs
the relationship between surface stress and deflection is given by Stoney’s formula:
∆𝜎 =

𝐸𝑡 2
∆𝑧
3(1 − 𝜈)𝐿2

( 15 )

where ∆𝑧 is the cantilever deflection, 𝐸 is the elasticity modulus, 𝜈 is the Poisson ratio, 𝑡
is the thickness of the cantilever and 𝐿 is the effective length, measured as the distance
from the base of the cantilever to the point where the deflection is read out by the laser
(Fritz, 2008). Molecular adsorption onto the surface creates surface stress and causes
deflection. This surface stress is proportional to the analyte concentration that is adsorbed
to the surface (Ji and Armon, 2010). The dynamic-mode, or resonance mode, mechanical
biosensor is not quasistatic. Instead, oscillation occurs with resonance frequency that
changes when molecules land on the cantilever. For instance, when mass is added the
resonance frequency is lowered. The basic resonance frequency of the cantilever is
modeled like the behavior of a harmonic oscillator, given by:

𝑓=

1 𝑘𝑠𝑝𝑟𝑖𝑛𝑔
√
2𝜋
𝑚∗

( 16 )

where 𝑘𝑠𝑝𝑟𝑖𝑛𝑔 is the spring constant and 𝑚∗ is the effective mass that considers the
cantilever geometry and mass distribution along the cantilever (Fritz, 2008). This type of
cantilever allows variance in the operating environment and mode. For example, these can
be used in humid environments and for continuous operation (Arlett et al., 2007). A
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disadvantage to the cantilever method is that it usually functions in air samples only,
instead of liquid (Kubicek-Sutherland et al., 2017). This makes this technique less valuable
to biomarker detection in clinical applications.
The specific output signal of the cantilever biosensor depends on the technique used
for detection. The detection of the deflection of the cantilever beam, caused by either a
change in surface stress or resonance frequency, plays a part in all types. However, the
method in which it is accomplished varies based on the sensor design. Commonly used
techniques include measuring the optical beam deflection (changes in reflection angle of
optical beam), piezoresistivity (changes in resistivity caused by applied strain),
piezoelectricity (changes in voltage produced by material under mechanical stress),
interferometry (changes in refractive index) and capacitance (measurement of cantilever
displacement) (Alvarez et al., 2008). An example of a piezoresistive microcantilever
biosensor and the transduction techniques used is presented later.
Some other types of mechanical biosensors include whispering-gallery microcavity
(WGM), optical microring resonators (MRRs), and nanowire biosensors. Mechanical
biosensors can be categorized into four groups depending on the relationship between the
analyte and the sensor. Group one includes affinity-based assays, which use high
specificity between the target and the functionalization at the surface. This is done to
achieve very selective target identification and capture, such as between antigens and
antibodies. Group two includes fingerprint assays, which identify a target through
distinctive binding affinities to an ensemble of sensors. This depends on an assortment of
less-selective functionalization layers. Group three includes separation-based assays, in
which spatiotemporal separation of analytes is permitted due to chemical affinities between
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immobilized species. Group four includes spectrometric assays, where identification is
performed using the mass or optical properties of the target analyte (Arlett et al., 2007).
Mechanical biosensors have been used for the detection of cardiac biomarker CRP
using self-sensing piezoresistive microcantilever sensors and antigen-antibody interaction
(Wee et al., 2005). The experiment conducted by Wee et al. (2005) utilized the static mode
or surface-stress method, and the piezoresistive microcantilever sensor allowed for
electrical detection via surface stress changes of antigen-antibody specific binding. An
internal and external half dc-bias Wheatstone bridge was measured to provide the electrical
measurement of change in sensor resistance and was used to measure the piezoresistive
induced voltage. Figure 2.18 shows the resulting piezoresistive response curves, that are a
result of static deflection of the cantilevers, at different CRP concentrations. It is shown
that the output voltage of the sensor was proportional to the concentration of CRP in
solution.

Figure 2.18 Output voltage as a function of CRP concentration (Wee et al., 2005).
Reprinted from Biosensors and Bioelectronics, 20, K.W. Wee, G.Y. Kang, J. Park, J.Y.
Kang, D.S. Yoon, J.H. Park, T.S. Kim, Novel Electrical Detection of Label-free Disease
Marker Proteins Using Piezoresistive Self-sensing Micro-cantilevers, 1932-1938, 2005,
with permission from Elsevier.
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This suggested that the microcantilever sensor design is effective for the detection of CRP.
A NiCr strain gauge cantilever biosensor has been utilized for the detection of the
addition of amyloid beta (A𝛽)(1-40) protein in human serum (Taniguchi et al., 2017).
Evidence has suggested that a crucial factor in the development of Alzheimer’s disease is
the interaction between A𝛽 and the cell membrane (Zhang et al., 2017). More specifically,
the interaction with cerebral nerve cells and the buildup of A𝛽 on these cells. Using the
cantilever microsensor design combined with a droplet-sealing structure, Taniguchi et al.
(2017) were able to show improvements in this sensor by using a digital filtering procedure
to eliminate external noise, and by incorporating cholesterol to suppress liposome and
protein interactions in the human serum. They were able to conclude that with these
additions the cantilever biosensor is able to detect low-concentrated A𝛽 in human serum.
2.2.3

Biosensors On-a-Chip
Biosensors on-a-chip is a technology that combines microfluidics, a lab-on-a-chip

technology, with biosensors. Microfluidics can be combined with different biosensing
platforms, such as electrochemical or optical, to create a more robust diagnostic tool. A
microfluidic biosensor is a fluidic system that encompasses micro-sized channels to aid in
the detection of a given target molecule. This type of biosensor encompasses two types of
channel flow: pressure-driven flow and electrokinetic flow. Using an electric field instead
of a pressure gradient may be preferable to drive channel flow since pressure-driven flow
becomes more challenging as channel size decreases (Prakash et al., 2012). Reynolds
number describes fluid flow and is given as:
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𝑅𝑒 =

𝜌𝑑𝜐
𝜂

( 17 )

where 𝜌 is the fluid density, 𝑑 is the characteristic length or dimension of the microchannel,
𝜐 is the flow rate of the fluid, and 𝜂 is the fluid viscosity (Kaur et al., 2018). The
concentration of target molecules and the speed of target molecule detection is governed
by basic physics of mass transport and reaction time. The trade-off between detection speed
and concentration has been investigated and is evident through different microfluidic
designs that have developed over the years. A higher fluid velocity is required for a faster
detection speed, however, the time required for the molecule to diffuse is the limiting
factor. The characteristic time scale for the biosensor, 𝑡𝑐 , is therefore expected to scale
according to:
𝑙𝑐2
𝐷

( 18 )

where 𝑙𝑐 is the characteristic length of the device and 𝐷 is the diffusivity of the target
molecule.
There are three different microfluidic systems: continuous flow, droplet-based, and
digital microfluidic (DMF). Continuous flow systems can by pressure driven or
electrokinetic and provide a motion of continuous fluid in micro-channels. Droplet-based
systems are pressure driven and provide droplets in micro-channels using streams of
immiscible fluids. DMF involves electrowetting on dielectric or dielectrophoresis and
provides discrete droplets on an array of planar electrodes. These different systems are
shown schematically in Figure 2.19.
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Figure 2.19 Schematic of three microfluidic systems (a) continuous; (b) drop-based; and
(c) digital (Luka et al., 2015). (https://creativecommons.org/licenses/by/4.0/legalcode)
(no changes made)

Each type of the three microfluidic systems presented provides integrated sensing
applications for the three most common biological recognition elements used in
microfluidic devices: enzymes, antibodies, and aptamers (Luka et al., 2015). As with all
biosensors, the signal that results from the interaction between the analyte and the
biological recognition element is modified by a transducer. However, the readout that
occurs depends on the particular biosensor integration.
Microfluidic biosensors are most commonly made of silicone, glass or types of
polymers (Prakash et al., 2012). Further, PDMS is the most popular material due to
advantageous qualities such as biocompatibility, easy handling, and low cost (Kaur et al.,
2018). Microfluidic designs allow for target molecule detection in small concentrations,
which is beneficial for clinical use. This aspect is also beneficial since the use of small
concentrations means a reduction in the use of costly reagents (Xu et al., 2018). Some other
notable advantages include quicker diagnostics through the manipulation of the sensor
geometry and highly sensitive real-time measurements that eliminate non-uniformity and
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non-homogeneity. A few disadvantages of microfluidic biosensors include undesirable
adsorption of non-specific molecules and interference from solutions (Prakash et al.
2012)(Kaur et al., 2018).
Microfluidic techniques have been used in conjunction with electrochemical
biosensors to create a method for cholesterol monitoring (Kaur et al., 2018). This design
utilizes Nickel Oxide (NiO) thin film as the material for the immobilization of cholesterol
oxidase enzyme and PDMS for the microchannel composition. The two electrode, three
microchannel biosensor was created on glass substrate using photolithography. Cyclic
voltammetry and chronoamperometry measurements were performed. The device proved
capable of a wide range of cholesterol detection with less sample consumption and high
sensitivity. It also is capable of a lower detection limit of 0.10 mM. Diluted serum samples
were used to validate the biosensor and proved its performance is accurate and comparable
to commercially accepted methods. Amperometric data obtained from electrochemical
studies is shown in Figure 2.20.
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Figure 2.20 (a) amperometric curves as a function of cholesterol concentration (b)
calibration curve (c) comparison to control (d) selectivity (Kaur et al., 2018). Reprinted
from Sensors and Actuators B, 261, G. Kaur, M. Tomar, and V. Gupta, Development of a
Microfluidic Electrochemical Biosensor: Prospect for Point-of-Care Cholesterol
Monitoring, 260-466, 2018, with permission from Elsevier.

Interestingly, in recent years microfluidic biosensors have been coupled with
smartphones to create smartphone-based microfluidic biosensors for point-of-care use.
Research shows that these can provide accurate and rapid point-of-care detection. These
also minimize downsides like cost, size and operational skill by the professional. These are
still in the laboratory phase and present further research and challenges, such as the issue
that miniaturization could decrease the accuracy and sensitivity compared to conventional
testing instruments already developed (Xu et al., 2018).
Microfluidic biosensors allow for a wide range of designs and techniques. For
example, Singh et al. (2019) and Mohammed and Desmulliez (2014) both present a

44

microfluidic system to detect CVD biomarker cardiac troponin I (cTnI). Singh et al. (2019)
created a microfluidic biosensor using a soft lithography technique and integrated Ni3V2O8
hollow-nanospheres that were modified with chitosan. This design proved to have high
sensitivity and selectivity and a low limit of detection, with a LOD for cTnI of 5 pg/ml.
Mohammed and Desmulliez (2014) created a microfluidic biosensor consisting of an
autonomous capillary system with embedded optical components. This design proved to
also provide high sensitivity, as well as advantages such as portability and low power
consumption. However, the limit of detection was demonstrated to be 24 pg/ml for cTnI.
This is still shown to be within the limits for clinical applications, but higher than the LOD
of the previous design.

2.3

Unmet Needs and Possible Future Directions
Although biosensor research and development has made great strides and is

consistently evolving, there are still gaps in the current research. One such gap is the
medium and condition in which the biosensor is tested in. In order to confidently conclude
that a biosensor is equipped for point-of-care use and in-situ monitoring, the testing of the
biosensor must occur in such conditions. A shortcoming that we have seen throughout the
literature is that many biosensors are tested only in a lab setting, often in artificial media.
Going forward, testing would also need to be conducted in the required human media
(blood, cerebral spinal fluid, etc.) and in a clinical, point-of-care setting. Human blood, for
example, provides a complex environment for testing and requires the sensing method to
exhibit a high level of selectivity towards the analyte or biomolecule being sensed. Having
a biosensor that performs accurately in a complex environment would prove very
beneficial, if not crucial, for clinical needs. Another issue we have seen throughout the
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literature is the need to improve the long-term performance of the biosensor. This ties in to
the stability of the sensor reducing over time and with use. This is not an issue for sensing
methods that are intended as single use. However, for those methods that are intended to
be reusable, the stability and performance over time needs to be examined in order to be
confident that results after months of use are as accurate as the results seen on first use.
Lastly, biosensors have shown to lack reproducibility in results. Variance in results from
one sensor to another sensor of the exact same design is not acceptable in a research or
clinical application and could lead to false results.
In all, biosensor research and development are progressing swiftly. Encouraging
improvements have been made, however, an increase in sensitivity, selectivity,
miniaturization and integration is still needed to successfully meet the requirements for a
point-of-care biosensor device. Biosensors-on-a-chip, as previously discussed, provide a
promising solution to achieve this goal. This lab-on-a-chip technology is relatively newer
and less researched. More consideration and development should be done in this area of
design to move towards more integrated systems with more complex biosensing
capabilities.
Future research should also be performed in the areas of wearable biosensors and
in-vivo biosensors. Success with these forms of biosensors would provide great value to
the medical field, as it would allow for interactive, real-time data collection and analysis
with the patient or individual wearing it. Recent glucose sensors for individuals with
diabetes have paved the way for this technology. Now, this should be expanded on to reach
more areas of diagnosis and detection.
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For the detection of cholesterol in human blood, the most commonly used methods
for detecting cholesterol concentration for diagnostics involve complex laboratory
equipment and user training. A sensitive and easy to use electrochemical biosensor would
provide the same ability as current methods but with simplicity and point-of-care
capability. An ideal solution could be to develop a detection method that achieves two
functions. One function being a biosensor designed with a bioreactor type of environment
that would allow the study of drug effects on cholesterol concentration, and the second
function being in vivo detection of cholesterol.
New biomarkers are being explored for the diagnosis and understanding of
Alzheimer’s disease. One such biomarker is amylin production and hyperamylinemia.
Based on research done by Jackson et al. (2013), amylin was examined as a potential
second amyloid in Alzheimer’s disease. Accumulation of amylin in the brain was assessed
for three groups: diabetic patients with vascular dementia or Alzheimer’s disease, nondiabetic patients with Alzheimer’s disease, and healthy controls of the same age.
Interestingly they found that, in addition to patients with diabetes, amylin deposition was
identified in brain parenchyma and blood vessels of non-diabetic patients with Alzheimer’s
disease. This suggested that the formation of amylin amyloid in the wall of cerebral blood
vessels could result in the inability to get rid of AB from the brain. This failure could
contribute to the cause of Alzheimer’s disease. Our work on the design of a biosensor that
can accurately distinguish and detect this biomarker will benefit this research by providing
a rapid and accurate means of detection and monitoring.
The importance and necessity of portable, rapid and accurate biosensors is
undoubtedly seen through the testing response for the novel and unfamiliar severe acute
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respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus (COVID-19) taking
place in our world today. This pandemic has been a shock to the world and due to its
novelty, there were no prior approved testing methodologies, unlike the testing for a more
common virus like influenza. This required emergency testing methods to be developed
and implemented under an Emergency Use Authorization (EUA) by the FDA. One of the
most common methods used is a rRT-PCR panel, however, the drawback of this method is
long turn around rates. This has left patients waiting up to a week to get their results,
potentially delaying their treatment and increasing their likelihood of infecting others
without knowing. The situation is very fluid and new technologies are emerging daily
(Emergency Use Authorization, 2020).
In response to the need for a rapid diagnostic test for COVID-19, companies and
researchers are working to develop such methods. One of the technologies emerged from
Cepheid, who has produced an automated molecular test that provides detection in
approximately 45 minutes (“Xpert Xpress”, 2020). Even more rapid, Abbott has developed
a molecular point-of-care test that can deliver positive results in 5 minutes and negative
results in 13 minutes (“Detect COVID-19”, 2020). Both methods leverage the principles
of each companies testing platform for influenza and RSV testing.
Many issues have been encountered with the testing capabilities developed for
COVID-19. Some issues include the difficulty in handling the constant mutation of the
virus, dealing with both false negative and false positive results, and the complexity of
commonly used and approved methods for virus detection.
This pandemic is a prime example of the need for rapid and accurate biosensors for
point-of-care detection and diagnostic use. Their creation for the detection of previous
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coronavirus outbreaks, such as the electrochemical immunosensor proven for the detection
of MERS-CoV, shows that biosensor application for the detection of such viruses is
possible and extremely crucial (Layqah and Eissa, 2019).

2.4

Conclusion
Biosensors are a promising field for creating miniature, rapid, specific and

reproducible detection systems that can be used in the research and clinical fields. In-situ
diagnostics and point-of-care monitoring are essential for the medical system today. All of
the sensor types discussed, electrochemical, optical, microfluidic, and mechanical, have
had success and provide necessary advantages. However, further work needs to continue
to optimize these biosensors and to minimize as many disadvantages as possible. For
example, maintaining sensitivity and specificity with miniaturization, and improving
biosensor longevity are problems that are continually being explored. It is also clear that
while some biosensors are employed and tested in human serum, others are limited by only
being tested artificially. Further testing needs to be performed to ensure the success and
potential clinical use of these biosensor designs.
Biosensors have proven to be a reliable source for the detection of many different
biomarkers related to cardiovascular disease and Alzheimer’s disease. However, the
research presented is just the beginning. Continued efforts need to be made to have these
sensors optimized and able to be used as a standard in clinical monitoring and diagnosis.
Additionally, other less common biomarkers are being discovered and researched that may
have a large impact on the treatment of both diseases. Having the ability to detect such
biomarkers quickly and efficiently through the use of biosensors could lead to significant
breakthroughs in monitoring and treating such life-altering diseases.
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CHAPTER 3.

3.1

DEVELOPMENT OF A FLUIDIC, CHIP-BASED GLUCOSE
BIOSENSOR

Introduction
Based on the needs identified in chapter 2 regarding improving the capability of

biosensors for the detection and monitoring of different critical biomarkers, the goal of this
research was to combine microfluidics and a chip-based biosensor to develop a device for
the detection of glucose. A combined microfluidic biosensor platform provides many
desired advantages, one being the ability to perform continuous monitoring. This capability
presents a device that would meet current needs and improve biomarker monitoring within
both a clinical and research setting.
Currently, there are continuous glucose monitors (CGM) on the market that are
used by individuals who have diabetes. According to the National Institute of Diabetes and
Digestive and Kidney Diseases (Russell, 2017), CGM devices are used by those with type
I diabetes, and rarely used by individuals with type II diabetes, as research is still being
done on how these devices would benefit those with type II. CGM devices also reportedly
need improvement in accuracy and ease of use, requiring a finger-stick glucose test twice
a day to compare results against a standard meter. It is also reported that CGM devices
can’t be used as the only resource for treatment decisions, a finger-stick glucose test is still
required. Given all of this, CGM devices are a step in a positive direction, however, the
standard finger-stick glucose test is still used for treatment decisions, for persons with type
II diabetes, and present a cheaper alternative than the CGM (Russell, 2017). A microfluidic
glucose biosensor could provide another option to bridge these gaps by providing an

50

inexpensive, easy to use device that would allow for glucose monitoring by clinicians,
while also providing an effective monitoring method for researchers.
To create a successful microfluidic glucose biosensor we took a continuous
improvement approach by testing different concentration ranges and experimental setups
to reach our final microfluidic design. This chapter first gives an overview of the electrodes
used, along with the surface characterization performed. The biofunctionalization process
is then described, followed by methods and results of glucose detection performed at high
and low ranges of glucose concentration. The chapter concludes with the final microfluidic,
chip-based platform design, covering the methods and results, followed by the longevity
and robustness testing of the biosensor.

3.2

Screen Printed Electrodes
Three-electrode screen-printed electrodes (SPE) consisting of a ceramic base, silver

reference electrode, gold working electrode and gold counter electrode were purchased
from Metrohm USA, Inc. (Riverview, FL, USA). Two different models of the Metrohm
SPE were purchased, each with a different temperature of gold screen-printed ink. The AT
model SPE is made with gold ink that is cured using a high temperature process (~900C),
compared with the BT model SPE made with gold ink that is cured using a low temperature
process (~150C). SEM images provided by Metrohm of each of the working electrodes
show the BT models have a rougher, more porous surface than the AT models (Figure 3.1).
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Figure 3.1 SEM images of the working electrode for the AT model SPE (high
temperature cured gold) and the BT model SPE (low temperature cured gold) (Metrohm).
Further information provided by Metrohm explains that the behavior of the SPE’s
could be similar or differ depending on the application of use. To confirm, a surface
characterization experiment to the gold working electrode on the SPE was performed by
running cyclic voltammetry (CV) on each type of SPE. This experiment was performed by
placing the chip sensor in a solution of phosphate buffered saline (PBS) containing 5mM
potassium ferricyanide (Sigma-Aldrich, St. Louis, MO, USA). An external glass Ag/AgCl
electrode and platinum gauze were used as the reference and counter electrodes,
respectively. The gold working electrode on the SPE along with the external reference and
counter electrodes were placed in a beaker containing the prepared solution with a stir bar.
Stirring is to facilitate convective mass transport in addition to the slow diffusion. CV
experiments were performed from +0.7 V to -0.15 V to +0.7V for 20 cycles. Four different
scan rates were used: 50 mV/s, 100 mV/s, 150 mV/s, and 200 mV/s. The stir settings were
adjusted to reach optimal results for each scan rate.
Figure 3.2 provides a sample of the raw data, showing the last cycle of the CV
experiment for each model of SPE at 50 mV/s and 150 mV/s scan rate. The effect of scan
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rate on current can be observed by comparing the two graphs. One characteristic that was
consistent with expectations is that the standard potential doesn’t change with a change in
scan rate. The data also shows that as the scan rate was increased, the resulting current
values also increased, which was to be expected. When the scan rate increases the overall
time decreases, so an increase in scan rate results in a decrease in the diffusion layer, and
vice versa. As summarized in Table 3.1, to examine this data further, the area under each
CV curve was taken by using the trapezoidal rule. The area under the curve, or integration
with respect to time, gives the surface charge (mC). The area under the curve was
calculated between +0.2 V and +0.4 V for the 20th cycle of each CV curve. This potential
range was chosen to eliminate the noise interference, especially below +0.2V.
Additionally, the current differentials for the 20th cycle were calculated between the
positive and negative ends of each curve by taking the difference of current values at +0.7V
and -0.15V.
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AT vs. BT at 150 mV/s Scan Rate
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Figure 3.2 Sample of cyclic voltammetry data for AT and BT model SPE at 50 mV/s and
150 mV/s scan rates. Curves shown represent the last cycle of the cyclic voltammetry
experiment.
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0.1175
0.1166

Mean
Surface
Charge
(mC)
0.1133
0.1166

Surface
Charge
Stdev
(mC)
0.0042
0.0036

0.0732
0.0777

0.0782
0.0731

0.0756
0.0742

0.0588
0.0737

0.0585
0.0725

0.0657
0.0765

0.0687
0.0630

0.0614
0.0732

0.0711
0.0731

Scan Rate
(mV/s) /
Sensor Model

Surface
Charge 1
(mC)

Surface
Charge 2
(mC)

Surface
Charge 3
(mC)

50 / AT
50 / BT

0.1091
0.1130

0.1132
0.1203

100 / AT
100 / BT

0.0754
0.0718

150 / AT
150 / BT
200 / AT
200 / BT

Mean
Differential
(mA)

Differential
Stdev (mA)

0.2457
0.2367

0.0070
0.0068

0.0025
0.0031

0.2507
0.1854

0.0063
0.0195

0.0610
0.0742

0.0040
0.0020

0.2706
0.2620

0.0010
0.0073

0.0671
0.0699

0.0051
0.0059

0.2906
0.2844

0.0052
0.0097

Table 3.1 Data obtained from cyclic voltammetry experiments performed on bare AT &
BT working electrodes. Three experiments were performed at each scan rate and the
mean area value was calculated using the 20th cycle. The mean differential at the 20th
cycle is given for each scan rate & model.

The data shows that at 50 mV/s, 150 mV/s, and 200 mV/s the BT model has a slightly
larger surface charge, inferred from a larger area under the curve, and at 100 mV/s the AT
model has a slightly larger surface charge. The instance at 100 mV/s presents an outlier to
the observed trend. The surface charge can then be divided by the surface area of the
working electrode to determine the charge density. The diameter of the circle working
electrode is 4 mm, which provides a surface area of 12.57 mm2. The resulting charge
density values are given in Table 3.2.
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50 /
AT

Scan Rate / Model

50 /
BT

100 /
AT

100 /
BT

150 /
AT

150 /
BT

200 /
AT

200 /
BT

Charge Density Run 1
(mC/mm2)

0.0087 0.0090 0.0060

0.0057

0.0047

0.0059

0.0055

0.0050

Charge Density Run 2
(mC/mm2)

0.0090 0.0096 0.0058

0.0062

0.0047

0.0058

0.0049

0.0058

Charge Density Run 3
(mC/mm2)

0.0093 0.0093 0.0062

0.0058

0.0052

0.0061

0.0057

0.0058

Mean Charge Density
(mC/mm2)

0.0090 0.0093 0.0060

0.0059

0.0049

0.0059

0.0053

0.0056

Stdev (mC/mm2)

0.0003 0.0003 0.0002

0.0002

0.0003

0.0002

0.0004

0.0005

Table 3.2 Charge density values at each scan rate for AT & BT model. Values calculated
by dividing the area under the CV curve by the surface area of the working electrode.

The charge density data can be analyzed to distinguish differences between the surface of
the AT vs. BT working electrode. Although both electrodes measure 4 mm in diameter, the
porous composition of the BT electrode could provide slightly more working surface
compared to the smoother AT electrode surface. A two-tailed t-test with =0.05 was
utilized to determine if a significant difference exists between the two surfaces based on
the charge density at each scan rate. At a scan rate of 150 mV/s a statistically significant
difference is shown with a p-value of 0.007, which is less than 0.05. At a scan rate of 50
mV/s, 100 mV/s, and 200 mV/s, the difference is not statistically significant, with p-values
of 0.353, 0.582, and 0.584, respectively. The effect the surface has on the sensor
biofunctionalization and detection performance will be examined through biomarker
detection experiments.
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3.3

Sensor Biofunctionalization
Prior to use each sensor was cleaned using the RCA-1 method, which involves the

removal of organic contaminants using a 5:1:1 solution of DI water, ammonium hydroxide
(Sigma-Aldrich, St. Louis, MO, USA) and hydrogen peroxide (Sigma-Aldrich, St. Louis,
MO, USA). After cleaning, the sensor is rinsed in DI water, dried and prepared for the
biofunctionalization steps. The enzymatic biofunctionalization process involves glucose
oxidase (GOx) being functionalized on the working electrode through the
electropolymerization of pyrrole. Conceptually, a positive potential is applied to the system
to pull electrons away and facilitate the pyrrole to polypyrrole reaction that is required.
Visually, this process is shown in Figure 3.3. This process was performed using two
different methods, first using a beaker then using a PDMS well. The PDMS well provided
necessary improvements for the electropolymerization process, which will be discussed.

Figure 3.3 Schematic of the biofunctionalization process for the glucose detection sensor.
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Initially, this process was performed in a 10 mL beaker with a two-electrode setup,
using the gold working electrode on the sensor and an external platinum gauze strip as the
counter electrode. The on-chip counter and reference electrodes were taped over with
masking tape to prevent any unwanted contact with the electropolymerization solution.
This was performed galvanostatically using a Keithley 2450 SourceMeter SMU
(Tektronix, Beaverton, OR, USA). The sensor was placed inside the beaker containing
solution and chronopotentiometry experiments were carried out in 0.1M PBS containing
0.1 mM pyrrole (VWR, Batavia, IL, USA) and 1 mg/ml GOx (Sigma-Aldrich, St. Louis,
MO, USA). The deposition current of 10 A was applied for 7.5 minutes (450 seconds) for
AT electrodes and 4 minutes (240 seconds) for BT electrodes.
The time needed for functionalization was determined by performing optimization
experiments on each sensor model. This was completed by applying different timed
amounts of deposition, testing the glucose detection response of each sensor, and then
comparing the slopes and R2 values of each corresponding calibration curve. The condition
that produced the highest slope was chosen as optimal. This data is presented in Table 3.3.
The applied current was kept constant at 10 A and the initial times performed were 7, 13
and 19 minutes. The BT sensor was later tested further with less time since it was observed
that deposition occurred more quickly than on the AT sensor. This observation was to be
expected based on the different surface properties of the working electrode surfaces.
Through this optimization the previously stated electropolymerization times of 7.5 minutes
for AT electrodes and 4 minutes for BT electrodes was determined.
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AT
(7 min.)

AT
(13 min.)

AT
(19 min.)

BT
(7 min.)

BT
(13 min.)

BT
(19 min.)

Slope
(A/M)

2

1

1

3

2

1

R2

0.9879

0.9545

0.9973

0.9665

0.7778

0.8801

Table 3.3 Optimization data for the AT and BT model sensor for the working electrode
electropolymerization. Slope and R2 values obtained from glucose detection testing of
functionalized sensors.

To improve on this initial setup, a PDMS well was created that contained a circular
well with a diameter slightly larger than the diameter of the on-chip working electrode.
This design is shown in Figure 3.4. This design allows for solution to be applied only on
the working electrode without having to tape over the on-chip reference and counter
electrodes, preventing any tape residue or surface disturbance. This method also reduces
the amount of solution needed to perform the functionalization.

Figure 3.4 The left schematic shows the PDMS well used for biofunctionalization of the
sensor. The right schematic provides a cross sectional view of the design.

The PDMS well was clamped onto the sensor and a syringe with a blunt needle placed into
the well. The needle tip was positioned close to the working electrode without making
contact to the surface. The needle tip was also wrapped in conductive tape, which is then
connected to the machine, allowing the metal needle to function as the counter electrode
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for the two-electrode system setup. The deposition solution was pumped from the syringe
into the well, and the solution was removed from the well and replaced periodically
throughout the experiment. For this method, chronopotentiometry experiments were
carried out in 0.1 M PBS containing 0.2 mM pyrrole and 1.97 mg/mL GOx. The deposition
current of 10 A was applied for 6 minutes (360 seconds) for AT electrodes and 5 minutes
(300 seconds) for BT electrodes. These values were based off of visual observations and
previously optimized times.
Functionalized sensors were stored dry in the refrigerator at 4C. The storage
conditions of the sensors were optimized and this condition proved best compared with
sensor storage in PBS at room temperature and sensor storage in PBS at 4C. The success
of the storage conditions was based on the visual condition of the silver reference electrode
and the rate of degradation observed in glucose detection results after storage.

3.4

Methods for Glucose Detection
A positive potential was applied to the working electrode and an electron transfer

between the electrode and GOx occurs due to the redox reaction between GOx and glucose.
As shown in the following reaction, glucose is catalyzed by GOx, which leads to O 2
consumption and H2O2 production:
𝐺𝑂𝑥

𝐺𝑙𝑢𝑐𝑜𝑠𝑒 + 𝑂2 +  𝐻2 𝑂 →

𝐺𝑙𝑢𝑐𝑜𝑛𝑖𝑐𝑎𝑐𝑖𝑑 +  𝐻2 𝑂2

To assess the sensing capabilities of the biofunctionalized glucose detection sensor,
step-wise tests were performed at increasing concentrations of glucose. A three-electrode
setup was utilized, consisting of the silver reference, gold working, and gold counter
electrodes on the Metrohm screen-printed electrode. Four different methods were tested to
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perform the glucose detection experiments: low glucose concentration range, high glucose
concentration range, manual solution flow, and a microfluidic, chip-based platform.
3.4.1

Low Glucose Concentration Range
Testing was performed to determine the detection capabilities of the sensor within

a low concentration range of glucose. To facilitate this, an experimental setup using a
beaker containing solution was utilized. The biofunctionalized sensor was placed in the 10
mL beaker containing a 5 mL solution of phosphate buffered saline (PBS) (Sigma-Aldrich,
St. Louis, MO, USA) with 3 mM p-benzoquinone (Sigma-Aldrich, St. Louis, MO, USA),
included as a mediator. Amperometric current responses were collected via the
chronoamperometry technique on the PARSTAT MC multichannel potentiostat
(AMETEK, Berwyn, PA, USA). The biosensor was allowed to equilibrate in solution via
pre-conditioning for 30 minutes. The experiment was then performed at an electrode
potential of +0.35 V versus reference for a total of 25 minutes. After stabilization of the
current at 15 minutes (900 seconds), a controlled amount of glucose from a 1 M glucose
stock solution was added to the PBS / p-benzoquinone solution. Consecutive additions of
glucose were made each minute after for a total of 10 glucose additions. Manual stirring
was performed to promote solution homogenization.

3.4.2

High Glucose Concentration Range
Testing was also performed to determine the detection capabilities of the sensor

within a high concentration range of glucose. To examine this, a lower amount of solution
was able to be used. Based on this, the biofunctionalized sensor was placed in one well of
a 24-well plate with 1.5 mL solution of phosphate buffered saline (PBS) containing 3 mM
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p-benzoquinone.

Amperometric

current

responses

were

collected

via

the

chronoamperometry technique on the PARSTAT MC multichannel potentiostat. The
biosensor was allowed to equilibrate in solution via pre-conditioning for 30 minutes. The
experiment was then performed at an electrode potential of +0.35 V versus reference for a
total of 25 minutes. After stabilization of the current at 15 minutes (900 seconds), a
controlled amount of glucose from a 1 M glucose stock solution was added to the PBS / pbenzoquinone solution. Consecutive additions of glucose were made each minute after for
a total of 10 glucose additions. Manual stirring was performed to promote solution
homogenization.
3.4.3

Manual Solution Flow
Before moving to a microfluidic design, the response of the sensor to flow of

solution across the electrodes was experimented with manually. This method utilized the
capacity of the sensor to hold a drop of liquid covering the electrodes. The solution volume
chosen was 70 L, as this amount could be held comfortably over the electrodes without
overflow. To perform the detection experiments, the sensor was secured to a flat surface
and 70 L of solution composed of phosphate buffered saline (PBS) containing 3 mM pbenzoquinone was pipetted onto the surface. The biosensor was allowed to equilibrate in
solution via pre-conditioning for 5 minutes. The pre-conditioning time was shortened due
to the reduced amount of solution. The experiment was then performed at an electrode
potential of +0.35 V versus reference for a total of 15 minutes. After stabilization of the
current at 5 minutes (300 seconds), a new 70 L addition was made using one pipette,
while a second pipette was concurrently removing the previous solution. The addition
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solutions consisted of pre-determined amounts of PBS, p-benzoquinone and glucose and
were added to the electrodes starting from low concentration of glucose to high. These
solutions were made according to Table 3.4. Consecutive additions were made each minute
for a total of 10 additions.
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Addition
Number

PBS / pbenzoquinone soln.
(mL)

Glucose
(µL)

Molarity
(mol/L)

Clinical
(mg/dL)

1

1.5

5

0.0033

59.8

2

1.5

7

0.0046

83.6

3

1.5

9

0.0060

107.4

4

1.5

11

0.0073

131

5

1.5

15

0.0099

178.2

6

1.5

20

0.0132

236.8

7

1.5

25

0.0164

295.1

8

1.5

35

0.0228

410.4

9

1.5

45

0.0291

524.3

10

1.5

50

0.0323

580.7

Table 3.4 Amount of each solution and the corresponding molarity and clinical value for
each addition for glucose detection testing. The table shows the total amounts used to
create each solution, with each addition number resulting in a different final volume to
reach the desired molarity. However, the same volume was withdrawn from each
prepared solution to be used for an addition.

3.4.4

Microfluidic, Chip Based Platform
After examining the detection capabilities of the sensor at low and high glucose

concentrations and testing the sensor response to the flow of solution across the electrodes,
the next step was to incorporate the sensor chip with a microfluidic platform. To do this, a
PDMS microfluidic platform was designed and created in the lab. The design consists of
an inlet well and inlet channel that flows into a dome that covers the sensor electrodes, and
an outlet channel for solution to exit through. The inlet well, channels and dome are created
using a 3D printer and PLA material. The 3D rendering of this design is shown in Figure
3.5.
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Figure 3.5 3D rendering of the internal structure of the microfluidic platform.

This material was chosen based on its ability to be dissolved out of the of PDMS using
acetone. The PDMS was constructed using SYLGARD 184 Silicone Elastomer Kit and
a 10:1 ratio of silicone elastomer base to elastomer curing agent, degassed in a centrifuge
at 3200 rpm for 2 minutes. The entire platform was setup in a petri dish and PDMS was
poured to cover all structures. After 48 hours of curing, the PDMS platform was extracted
from the petri dish and the PLA structures were removed. A picture of the final PDMS
component with sensor is shown in Figure 3.6.
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Figure 3.6 PDMS component after removal from petri dish and PLA dissolution. A nickel
is shown for size reference.

A needle connected to tubing was inserted into the outlet channel and connected to a
syringe pump. A schematic of the entire experimental setup, and a cross sectional view, is
shown in Figure 3.7.

Figure 3.7 The top schematic shows the overall experimental setup for amperometric
glucose detection. The bottom schematic shows a cross sectional view of the combined
PDMS, chip based platform.
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The withdrawal function of the syringe pump was used to pull solution through the
microfluidic system at a rate of 0.1 mL/min. For detection experiments, the 10 solutions
shown in Table 3.4 were made and used. Before the experiment, 100 L of solution
composed of phosphate buffered saline (PBS) containing 3 mM p-benzoquinone was
pumped through the system, and the pump was paused when the well was emptied. The
sensor was allowed to sit in solution for pre-conditioning for 5 minutes. The experiment
was then performed at an electrode potential of +0.35 V versus reference for a total of 15
minutes. After stabilization of the current at 5 minutes (300 seconds), the first 100 L
addition was added into the well and the pump was started. Consecutive additions were
added to the well every minute after for a total of 10 different additions.

3.5

Results & Discussion
All methods used for glucose detection proved the detection capability of the

biosensor. However, as shown in the methods progression, continuous improvement was
done to reach the microfluidic, chip-based platform that provides the most robust and
desirable results.
3.5.1

Low Glucose Concentration Range
Utilizing a 10 mL beaker for the experimental setup to perform glucose detection

experiments allowed for detection testing of the biosensor at lower concentrations of
glucose, including within the physiological range of glucose levels, 3.9 – 7.1 mmol/L (70
– 130 mg/dL). Results proved the detection capabilities of the biosensor within this range,
with good linearity, 0.9979 for the AT sensor and 0.9978 for the BT sensor. Visually, the
raw data shows a large amount of noise, especially in the case of the AT sensor. This noise
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was likely due to the larger amount of solution the biosensor was placed in, combined with
the movement caused by manual stirring. To construct the calibration curve, the final
current at each time segment was taken and plotted. Based on this, the sensitivity, given by
the slope of each calibration curve, was higher for the AT sensor than the BT sensor in this
case. The sensitivity was 0.04 A/mM and 0.03 A/mM for the AT and BT sensor,
respectively.
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Figure 3.8 The top plot shows the raw data for AT sensor with glucose additions as a
function of time. Additions began at 900 seconds and a controlled amount of 1M glucose
stock solution was added every 60 seconds. The bottom plot shows the corresponding
calibration curve.
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Figure 3.9 The top plot shows the raw data for BT sensor with glucose additions as a
function of time. Additions began at 900 seconds and a controlled amount of 1M glucose
stock solution was added every 60 seconds. The bottom plot shows the corresponding
calibration curve.
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3.5.2

High Glucose Concentration Range
As an effort to reduce the noise experienced using the beaker, as well as testing the

detection capability of the sensor at higher glucose concentrations, the next step was using
the 24-well plate. By using one well in a 24-well plate, the amount of solution needed to
perform the experiments was reduced from 5 mL to 1.5 mL and glucose detection was
performed at higher concentrations of glucose. However, manual stirring was still required.
It is shown in the raw data for both the AT and BT sensor that the noise was significantly
reduced, and the desired step trend corresponding to an increase in glucose concentration
is more visible. This method also greatly increased the sensitivity of both sensors. In the
presented case, the resulting sensitivity was 7.91 A/M for the AT sensor and 8.12 A/M
for the BT sensor. In this experimental setup, the BT sensor showed higher sensitivity,
opposed to the AT sensor showing higher sensitivity in the previous setup. Both sensors
had high R2 values, 0.9983 for the AT sensor and 0.9971 for the BT sensor. However, a
limitation of this method is the inability to test the sensors within the physiological range
of glucose. Due to the lower starting volume in the well, the volume of glucose additions
required to obtain values within the physiological range was not achievable. This led to
further methods being pursued and improvements made.
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Figure 3.10 The top plot shows the raw data for AT sensor with glucose additions as a
function of time. Additions began at 900 seconds and a controlled amount of 1M glucose
stock solution was added every 60 seconds. The bottom plot shows the corresponding
calibration curve.
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Glucose Detection - High Concentration Range - BT
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Figure 3.11 The top plot shows the raw data for BT sensor with glucose additions as a
function of time. Additions began at 900 seconds and a controlled amount of 1M glucose
stock solution was added every 60 seconds. The bottom plot shows the corresponding
calibration curve.
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3.5.2.1 Combined Low to High Glucose Concentration Range
The data obtained from low glucose concentration range testing and high glucose
concentration range testing was then combined to examine the trend across the entire
concentration range. These plots are shown in Figure 3.12. In both the AT and BT case,
the combined currents follow the desired trend. More specifically, the current points at the
beginning of the high concentration plot follow in line with the current points at the end of
the low concentration plot. This trend is stronger in the BT data than the AT data. In both
instances, the sensitivity of the sensor to glucose is higher in the low concentration range
than high concentration range, which is to be expected. As the concentration is continually
increased saturation occurs leading to a lower sensitivity. The trends shown in this
combined data reiterates the capability of the functionalized glucose biosensor to detect
changes in glucose concentration across a wide concentration range.
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Figure 3.12 Combined calibration curve data for low glucose concentration and high
glucose concentration testing.
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3.5.3

Manual Solution Flow
Due to the setup of this method, particularly that the solutions for each 10 additions

were prepared separately, a wide range of glucose concentrations were able to be tested in
one experiment, including within physiological range. This method resulted in large spikes
that occurred during the transition of removing and replacing solution on the electrodes.
These spikes were likely a result of human capabilities and caused by potential nonuniformity of the flow of liquid. As solution was being removed and new solution added,
if any section of the electrodes were not covered in solution and exposed to air it resulted
in this large current spike. This was an aspect that improved with practice and repetition
but could not fully be eliminated. To create a calibration curve from this data, the final
steady state current from each time segment (before each spike) was taken and plotted.
This resulted in a sensitivity of 5.54 A/M and an R2 value of 0.9822. The sensitivity was
in-between that of the individual high and low concentration tests, being more similar to
that of the high concentration testing. The R2 value was lower than both previously tested
methods. For this method, only an AT sensor was tested.
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Figure 3.13 The top plot shows the raw data as a function of time, obtained by
performing glucose additions using two pipettes to manually simulate continuous solution
flow. Additions began at 300 seconds and continued every consecutive minute after with
increasing concentration of glucose solution. The bottom plot shows the corresponding
calibration curve.
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3.5.4

Microfluidic, Chip-Based Platform
Expanding on the principle of the manual flow of solution method discussed

previously, specifically flow of a small amount of solution across the electrodes, and the
broader, more encompassing range of glucose concentration, leads to the microfluidic,
chip-based platform. Similarly to the previous method, the microfluidic, chip based
platform allowed for testing across a wide range of glucose concentrations with one
experiment. With this method, the continuous flow of liquid across the electrodes produced
a steady current response without any external noise or environmental interference. The
steady state current at each time segment was taken and plotted to form each calibration
curve. This method showed a significant increase in sensitivity for both the AT and BT
sensor, with the AT sensor sensitivity being substantially higher than the BT sensor. In this
case, for the lower concentration detection, the average sensitivity (3 experiments) of the
AT sensor was 47.95 A/M, compared with 30.40 A/M for the BT sensor. For the higher
concentration detection, the average sensitivity (3 experiments) of the AT sensor was 24.68
A/M, compared with 14.99 A/M for the BT sensor. The AT sensor also showed a higher
linearity in both the low and high concentration range with an R2 value of 0.9992 (low) and
0.9983 (high), compared with the BT sensor R2 value of 0.9493 (low) and 0.9691 (high).
The response time, or the time from each addition to when 90% of the steady state current
is reached, was determined from the raw data. The response time was the same for each
sensor, both producing a fast response time of an average of 15 seconds. However, the limit
of detection (calculated using the formula LOD=3.3/S, where  is the standard deviation
of the response and S is the slope of the calibration curve) differed between the two models.
These values were determined using the lower range concentration data of three
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experiments taken on the first day of sensor testing. For the AT sensor, the LOD was
calculated as 0.02 mM. For the BT sensor, the LOD was higher at 0.11 mM.
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Figure 3.14 The top plot shows the raw data for AT sensor of glucose additions as a
function of time (average of 3 experiments). Additions began at 300 seconds and
continued every consecutive minute. 100 L of increasing concentration of PBS/pBenzoquinone/glucose solution was added to the well and pumped through the
microfluidic system. The bottom plot shows the corresponding calibration curves.
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Glucose Detection - Microfluidic - BT
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Figure 3.15 The top plot shows the raw data for BT sensor of glucose additions as a
function of time (average of 3 experiments). Additions began at 300 seconds and
continued every consecutive minute. 100 L of increasing concentration of PBS/pBenzoquinone/glucose solution was added to the well and pumped through the
microfluidic system. The bottom plot shows the corresponding calibration curve.
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3.5.5

Degradation Behavior of the Sensors
The longevity of each sensor, examined by looking at the sensitivity (slope), was also

tested over a period of 28 days. For the AT sensor, peak performance was observed on day
0 and a rise in performance was seen on day 10, followed by a steady decline. For the BT
sensor, there was a steady decline in performance after day 0, with a slight increase in
average performance observed on day 4. The data in Table 3.5 and Table 3.6 as well as the
graphed data in Figure 3.16 confirms that the AT sensor showed better overall
performance. The average sensitivity (based off of three separate runs of the experiment)
was higher for the AT sensor on every day of testing. The results for the AT sensor on day
28 of testing are most similar to the results on day 14 of testing for the BT sensor. To
confirm this further, a one-way repeated measurement ANOVA with an alpha of 0.05 was
performed between the AT and BT data. This resulted in a P-value of 0.0006. Since the Pvalue was less than alpha it can be concluded that the sensor model (AT vs. BT) had a
statistically significant effect on sensitivity. Additionally, a one-way repeated
measurement ANOVA was used to examine the effect of testing day on both the AT and
BT sensor separately. For the AT sensor and BT sensor, the resulting P-value was 7.13x1011 and

2.52x10-6, respectively. These values are both less than alpha and it can be concluded

that the testing day had a statistically significant effect on sensitivity for both the AT and
BT sensor. It’s also important to note that with the previous methods (sensor not attached
to a PDMS platform) the sensors were regarded as single use sensors, due to their rapid
decrease in performance and visual degradation of the reference electrode. The sealing of
the sensor to the PDMS platform, and subsequent storage at 4C in this sealed state, has
shown to preserve the capabilities of the sensor for an extended period of time. The
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environment within the seal seems to prevent the desiccation, or dehydration, of the
molecules.
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Day 0

Day 3

Day 6

Day 10

Day 14

Day 28

Slope

R2

Slope

R2

Slope

R2

Slope

R2

Slope

R2

Slope

R2

Run 1

35.88

0.9841

26.61

0.9880

20.58

0.9888

25.36

0.9897

*

*

8.38

0.9614

Run 2

37.96

0.9855

29.99

0.9889

25.02

0.9786

30.07

0.9974

16.57

0.9918

11.08

0.9832

Run 3

40.88

0.9895

26.68

0.9819

32.70

0.9874

19.31

0.9875

13.25

0.9933

Mean

38.24

0.9864

28.30

0.9885

24.09

0.9831

29.37

0.9915

17.01

0.9617

10.91

0.9793

Std
Dev

2.51

0.0030

2.39

0.0010

3.15

0.0050

3.72

0.0050

1.94

0.0030

2.44

0.0160

N/A

Table 3.5 Slope (sensitivity) and linearity (R2) data for the AT sensor over a 28-day
testing period. The values for each experiment and the average of all 3 experiments is
given.
*On Day 14, the first experiment run did not follow normal trends and it was determined
that further flushing of the microfluidic channel was needed before further detection
experiments were performed.

Day 0

Day 4

Day 6

Day 10

Day 14

Day 28

Slope

R2

Slope

R2

Slope

R2

Slope

R2

Slope

R2

Slope

R2

Run 1

18.79

0.9649

22.99

0.9969

12.14

0.9949

*

*

8.93

0.9965

2.44

0.7032

Run 2

22.92

0.9773

22.11

0.9920

21.62

0.9965

11.76

0.9882

10.33

0.9960

2.39

0.6339

Run 3

27.41

0.9557

26.30

0.9946

17.86

0.9924

13.81

0.9973

11.54

0.9862

4.28

0.9474

Mean

22.95

0.9659

23.80

0.9945

17.21

0.9946

11.83

0.9844

10.27

0.9929

3.04

0.7615

Std
Dev

4.18

0.0120

2.21

0.0020

4.77

0.0020

1.45

0.0060

1.31

0.0060

1.07

0.1650

Table 3.6 Slope (sensitivity) and linearity (R2) data for the BT sensor over a 28-day
testing period. The values for each experiment and the average of all 3 experiments is
given.
*On Day 10, the first experiment run did not follow normal trends and it was determined
that further flushing of the microfluidic channel was needed before further detection
experiments were performed.
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Figure 3.16 The average sensitivity (slope) per day of testing is shown for the AT sensor
(top) and BT sensor (bottom). Each sensor was tested at given intervals over a period of
28 days.
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3.5.6

Robustness of the Sensors
The robustness of the sensor was tested by performing different experiments from

high to low glucose concentration as opposed to low to high concentration, examining the
current response. This was done using the AT model sensors and completed the same day
as day 6 detection testing. For the first experiment, shown in Figure 3.17, once steady state
current was reached, DI water was added to the system at 300 and 360 seconds. At 420
seconds and every minute after, a glucose solution was added, starting from the highest
glucose concentration, and decreasing with each addition. The current response followed
the desired step trend in the decreasing direction. The steady state current at each time
segment (exempting the DI water additions) was taken to plot the calibration curve. This
resulted in a sensitivity of 27.83 A/M and an R2 value of 0.9616. The detection testing of
the AT sensor on day 6 resulted in a sensitivity value of 24.09 A/M. The similarity of
these two sensitivity values supports the robustness of the sensor capabilities.
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Figure 3.17 The top plot shows the raw data as a function of time. At 300 and 360
seconds, 100 L additions of DI water were added to the system. At 420 seconds and
every consecutive 60 seconds, 100 L of PBS/p-Benzoquinone/glucose solution was
added to the system, from high to low glucose concentration. The bottom plot shows the
corresponding calibration curve without the DI water additions.
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For the second experiment, shown in Figure 3.18, additions were alternated
between DI water and glucose solution. After steady state current was reached at 300
seconds, the highest glucose concentration was added, followed by an addition of
decreased glucose concentration. This pattern was repeated 3 more times, for a total of 3
DI water additions (420, 600 and 780 seconds) and 7 glucose concentration additions in
decreasing order (300, 360, 480, 540, 660, 720 and 840 seconds). The sensor responded as
expected to DI water additions and showed the appropriate decreasing step trend to glucose
additions. The calibration curve was created by dividing the data into four segments (300420 seconds, 480-600 seconds, 660-780 seconds and 840-900 seconds). The lowest steady
state current was taken from each of the four segments and plotted against the
corresponding concentration. This resulted in a sensitivity of 35.26 A/M and an R2 value
of 0.9513. This sensitivity value is similar to that produced by the normal detection testing
of low to high glucose concentration and the previous high to low glucose concentration
testing, further supporting the robustness of the sensor.
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Figure 3.18 The top plot shows the raw data as a function of time. At 420, 600 and 780
seconds 100 L additions of DI water were added to the system. At the remaining time
points, 100 L additions of PBS/p-Benzoquinone/glucose solution were added to the
system in order of decreasing glucose concentration. The bottom plot shows the
calibration curve (minus the DI water additions) constructed by taking the lowest steady
state current response per segment (300-420s, 480-600s, 660-780s, and 840-900s).
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3.6

Conclusion
Through continuous improvement in design and testing parameters, the microfluidic,

chip-based biosensor for glucose detection was successfully completed. This provides an
effective and promising platform for detection and continuous monitoring of glucose. The
microfluidic design paired with the amperometric chip delivers rapid, sensitive and
reproducible results, while maintaining a detection limit within physiological ranges of
glucose. This design allows for an easy to use method that could translate well for uses in
a research or clinical application. Based on this success, our goal of exploring the design
beyond solely glucose detection was able to be investigated.
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CHAPTER 4.
4.1

FLUIDIC, CHIP-BASED CHOLESTEROL BIOSENSOR

Introduction
In this chapter, further exploration of the fluidic, chip-based sensor beyond glucose

detection is discussed through the use of different functionalization methods to target other
important biomarkers, specifically cholesterol. Cholesterol is a critical biomarker that is
physiologically essential but can cause harm when present at elevated or reduced levels.
At elevated levels problems such as atherosclerosis, heart disease and nephrosis may occur
and at low levels hypothyroidism and anemia can be an issue (Rahman, 2014). Current
methods for cholesterol detection and measurement include fluorometric and colorimetric
enzymatic assays, gas and liquid chromatography, mass spectroscopy and classical
chemical methods based on the Abell-Kendall protocol. While all of these methods work,
they come with disadvantages, including multistep procedures, costly equipment and
materials, sample pretreatment requiring extensive training, and long processing times (Li
et al., 2018). A fluidic, chip-based biosensor that can quickly and accurately detect
cholesterol would provide a highly desirable option to combat these current disadvantages,
offering a device that is beneficial in both clinical and research applications.
In the following sections, the biofunctionalization process of the cholesterol
biosensor, the methods for detection and some obtained results are presented.

4.2

Sensor Biofunctionalization
Similar to the biofunctionalization process for the glucose biosensor, prior to using

each sensor was cleaned using the RCA-1 method, which involves the removal of organic
contaminants using a 5:1:1 solution of DI water, ammonium hydroxide (Sigma-Aldrich,
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St. Louis, MO, USA) and hydrogen peroxide (Sigma-Aldrich, St. Louis, MO, USA). After
cleaning, the sensor is rinsed in DI water, dried and prepared for the biofunctionalization
steps. The enzymatic biofunctionalization process involves cholesterol oxidase (ChOx)
(Sigma-Aldrich, St. Louis, MO, USA) being functionalized on the working electrode
through the electropolymerization of pyrrole (VWR, Batavia, IL, USA). Conceptually, a
positive potential is applied to the system to pull electrons away and facilitate the pyrrole
to polypyrrole reaction that is required. Visually, the biofunctionalization process is shown
in Figure 4.1.

Figure 4.1 Schematic of the biofunctionalization process for the cholesterol biosensor.

This process was performed using a similarly made PDMS well as shown in Figure
3.7. The PDMS well was clamped onto the sensor and a syringe with a blunt needle was
placed into the well. The needle tip was positioned close to the working electrode without
making contact with the electrode surface. The needle tip was also wrapped in conductive
tape, which was then connected to the PARSTAT MC multichannel potentiostat
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(AMETEK, Berwyn, PA, USA), allowing the metal needle to function as the counter
electrode in a two-electrode system setup. The deposition solution was pumped from the
syringe into the well, and the solution was removed from the well and replaced periodically
throughout the experiment. For this method, chronopotentiometry experiments were
carried out in 0.1 M PBS containing 0.2 mM pyrrole and 1.67 mg/mL ChOx. The
deposition current of 10 A was applied for 8 minutes (480 seconds) for AT electrodes.
Based on the previous results obtained for the glucose biosensors, only the AT model
electrodes were used based on the overall better performance. Functionalized sensors were
sealed to a PDMS microfluidic platform (constructed as discussed previously) and stored
dry in the refrigerator at 4C.

4.3

Methods for Cholesterol Detection
A positive potential was applied to the working electrode and an electron transfer

between the electrode and ChOx occurs due to the redox reaction between ChOx and
cholesterol. As shown in the following reaction, cholesterol is catalyzed by ChOx, and
results in a cholesterol ketone and hydrogen peroxide. The applied positive potential
facilitates the hydrogen peroxide redox reaction, which produces oxygen, hydrogen and
electrons.
𝐶ℎ𝑂𝑥

𝐶ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 +  𝑂2 →

4 − 𝐶ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑛𝑒 − 3 − 𝑜𝑛𝑒 +  𝐻2 𝑂2

𝐶𝑜𝑛𝑠𝑡𝑎𝑛𝑡𝑃𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙

𝐻2 𝑂2 →

𝑂2 + 2𝐻+ + 2𝑒 −

Similar to the glucose detection sensor, the sensing capabilities of the biofunctionalized
cholesterol sensor were assessed by performing step-wise tests at increasing concentrations
of cholesterol.
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A similar experimental setup was utilized, consisting of the three-electrode chip
sealed to a PDMS microfluidic platform as schematically shown in Figure 4.2. This
platform design was almost identical to the design used for the glucose detection. However,
an improvement was made by changing the shape of the dome over the electrodes. The
previous full-circle dome was modified to a half-circle dome for eliminating any dead
space for solution flow.

Figure 4.2 Schematic of the overall experimental setup for amperometric cholesterol
detection.

A needle with tubing was inserted into the outlet channel and connected to the syringe
pump. The withdrawal function was used to pull solution through the microfluidic system
at a rate of 0.2 mL/min. For detection experiments, a Matrix Plus Cholesterol Reference
Kit from Verichem Laboratories Inc. was used. The contents of this kit are shown in Table
4.1. The physiological range of total cholesterol that is classified as healthy is 125 to 200
mg/dL, with values above 200 mg/dL classified as high cholesterol. This kit provides a
range that encompasses physiological values. Although the solutions in this kit also contain
uric acid, it was determined that this was still a good option due to the wide range of premade cholesterol concentrations in solution and since it has been shown that uric acid
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provides minimal interference in cholesterol detection (Gao et al., 2019, Gholivand and
Khodadadian, 2014). It is also noted that the addition of a mediator into solution eliminates
possible interference (Wang and Hu, 2020). Based on this, a solution consisting of 10 mM
potassium ferricyanide (mediator) in PBS was added to each cholesterol solution prior to
detection experiments.
Cholesterol
Cholesterol
After Dilution After Dilution
with
with
Uric
Solution Cholesterol Cholesterol
Uric
PBS/Potassium PBS/Potassium
Acid
Level
(mg/dL)
(mM)
Acid (M)
Ferricyanide
Ferricyanide (mg/dL)
Soln.
Soln.
(mg/dL)
(mM)
A

40

1.034

23

0.604

2

0.000119

B

155

4.008

90

2.339

7

0.000416

C

270

6.982

158

4.073

12

0.000714

D

385

9.956

225

5.808

17

0.001011

E
500
12.930
292
7.543
22
0.001309
Table 4.1 The contents of the 5 solutions in the Matrix Plus Cholesterol Reference Kit
from Verichem Laboratories Inc. The kit provides the values in mg/dL. This table shows
mg/dL and M for reference. These 5 solutions were used for cholesterol detection testing.
Before the experiment, 300 L of phosphate buffered saline (PBS) containing 10 mM
potassium ferricyanide was pumped through the system, and the pump was paused when
the well was almost emptied. The sensor was allowed to sit in solution for pre-conditioning
for 45 minutes. During initial trial experiments it was determined that the functionalized
sensors for cholesterol detection required a longer pre-conditioning time than those for
glucose detection. The experiment was then performed at an electrode potential of +0.60
V versus reference for a total of 6 to 7 minutes, depending on current stabilization time.
After stabilization of the current at 1 to 2 minutes, a 200 L addition of the lowest
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cholesterol concentration solution (solution level A) was added into the well and the pump
was started. Consecutive 200 L additions of increasing cholesterol concentration (solution
level B through E) were added to the well every minute after for a total of 5 different
additions.

4.4

Preconditioning
Through preliminary testing and troubleshooting of the cholesterol biosensor, it was

determined that the sensor needed to be preconditioned through prolonged storage time at
4C to increase the overall sensitivity. A proper preconditioning step was determined by
first testing a newly functionalized sensor on Day 0 and Day 3. Day 0 represents the day
following sensor biofunctionalization and platform sealing. The sensor was kept in storage
at 4C in-between testing days. On Day 0 the detection experiment was run on the sensor
one time to observe results and pre-condition the sensor prior to storage. The results from
this experiment are shown in Figure 4.3. In contrast to subsequent testing, 100 L additions
of cholesterol solution were added instead of 200 L additions. Based on this test and the
pump withdrawal rate, it was determined that 200 L additions would be the best option
moving forward. It is shown in the graph that there was an initial spike as a result of the
first cholesterol addition, and then slight current increases when an addition of increased
concentration was added at 60, 90, 120, 150 and 180 seconds. However, the overall current
trend was decreasing with increasing cholesterol concentration, instead of stepped current
increases with increasing cholesterol concentration.
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Cholesterol Detection Day 0
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Figure 4.3 Raw data from cholesterol detection experiment performed on functionalized
cholesterol sensor. PBS/ferricyanide solution present on electrodes from 0-60 seconds.
Cholesterol solution additions of increasing concentration added at 60, 90, 120, 150 and
180 seconds.

Testing was then performed on Day 3 and five separate experiments were
performed. The sensor platform was placed in refrigerator storage at 4C for an hour inbetween the 3rd and 4th experiment. Experiments 1 through 3 and 4 through 5 were run
consecutively, including 45 minutes of pre-conditioning in-between each. The raw data for
the 1st experiment and 5th experiment are shown in Figure 4.4. On the first experiment, the
last addition of cholesterol (added at 360 seconds) wasn’t detected, whereas on the fifth
experiment it was (added at 300 seconds). Calibration curves were constructed by plotting
the steady state current value for each cholesterol concentration. The fifth addition of
cholesterol solution was detected on two out of the five experiments performed: run 3 and
run 5. For the experiments that didn’t detect the fifth cholesterol addition, only 4 points
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were used to construct the calibration curve. Calibration curves for experiment 1 and 5 are
shown in Figure 4.5. Based on this, the data was divided into two groups for comparison.
This data is presented in Table 4.2.
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Cholesterol Detection Day 3 Run 1
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Cholesterol Detection Day 3 Run 5
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Figure 4.4 Raw data from cholesterol detection testing on day 3. The top graph shows
raw data from the first experiment performed. The first cholesterol addition was added at
120 seconds and every 60 seconds after. The bottom graph shows raw data from the fifth
experiment performed. The first cholesterol addition was added at 60 seconds and every
60 seconds after.
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Cholesterol Concentration vs Current Day 3 Run 1
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Cholesterol Concentration vs Current Day 3 Run 5
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Figure 4.5 The top graph shows the calibration curve based on the first experiment and
includes the first 4 data points. The bottom graph shows the calibration curve based on
the fifth experiment and includes all 5 data points. This data is from Day 3 testing.
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Group

Experiment
Number

# of Points in
Calibration
Curve

1
A

2

4

4

3
B

Slope (A/mM)

R2

0.21

0.9618

0.33

0.6481

0.39

0.9783

0.19

0.6664

0.22

0.9458

5
5

Table 4.2 Slope and R2 values obtained from calibration curves. The first group of data
points doesn’t include the 5th cholesterol addition and the second group does.

Examining group A, it can be seen that the sensitivity of the sensor, or slope of
the calibration curve, increased with increased time. In other words, the more preconditioning the sensor had been exposed to, as well as the more experiments performed
on the sensor in one day, the higher the sensitivity to cholesterol. This same trend is
observed in group B. It is also interesting to note that experiment 3 and experiment 5
were both conducted when the sensor had been out of refrigerator storage for a longer
period of time. For example, prior to experiment 1 the sensor had been in refrigerator
storage for over 48 hours, and the 5th cholesterol addition wasn’t detected until
experiment 3. Prior to experiment 4 the sensor had been in refrigerator storage for 1 hour,
and the 5th cholesterol addition was detected on experiment 5. Although further
exploration would be needed, it is possible there is a correlation between the amount of
time in refrigerator storage to the amount of pre-conditioning time needed to reach an
acceptable sensitivity. This is also interesting due to the 45 minutes of pre-conditioning
performed on the sensor prior to any experiment. This means before the first experiment
is run the sensor is equilibrated in solution at room temperature for 45 minutes, likely
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reaching room temperature before the start of experiments. This suggests that the
temperature of the sensor at the time of testing isn’t the main factor causing this trend.
To explore the previously observed trends further and continue optimization of
the testing conditions, a second set of testing was executed on a newly functionalized
sensor with testing done on Day 0, Day 1, Day 2 and Day 3. Three experiments were
performed on each day of testing. A summary of the slope and R2 values obtained from
calibration curves for each run are given in Table 4.3.
Day 0

Day 1

Day 2

Day 3

Slope
(A/mM)

R2

Slope
(A/mM)

R2

Slope
(A/mM)

R2

Slope
(A/mM)

R2

Run 1

-0.26

0.8152

0.04

0.4753

0.04

0.4484

0.08

0.6594

Run 2

-0.16

0.7154

0.12

0.7145

0.02

0.1924

0.18

0.9849

Run 3

-0.10

0.5711

0.09

0.6625

0.09

0.9284

0.12

0.8627

Mean

-0.16

0.7006

0.08

0.6174

0.05

0.5231

0.13

0.8357

Std Dev

0.09

0.1227

0.04

0.1258

0.04

0.3736

0.05

0.1644

Table 4.3 Summary of the slope and R2 values obtained from calibration curves for each
experiment on every day of testing on the cholesterol sensor.
Similar to the previous set of data, on Day 0 the current followed a decreasing
trend, signified by negative slope values. By examining the raw data it is clear that there
were small peaks when a cholesterol addition was added, but that the decreasing trend
then followed. This reiterates the need for a conditioning period to increase the sensitivity
of the sensor. On Day 0 the magnitude of the slope and R2 value both decreased from run
1 to run 3. Given this, it appears the sensitivity of the sensor to cholesterol was slowly
increasing. As is visible from the calibration curves in Figure 4.6, in run 3 compared to

102

run 1, the points began to follow a curved trend instead of a straight line. This occurred
because the last three additions were decreasing less, suggesting an increasing sensitivity.
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Cholesterol Concentration vs Current Day 0 Run 1
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Figure 4.6 Calibration curves for all experiments performed on day 0 of cholesterol
testing.
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On Day 1 of testing the sensitivity was increased and the results followed a
positive trend the remaining days of testing. By examining the data given in Table 4.3 it
can be seen that the mean slope and mean R2 values were highest on day 3 of testing.
Based on this and the previous experimental timeline, the additional testing performed inbetween Day 0 and Day 3 didn’t seem to quicken the increased sensitivity. However, the
additional testing may have improved the consistency of sensitivity. When the sensor was
tested only on Day 0 and Day 3, the fifth cholesterol addition was detected on 2 out of the
5 runs. When the sensor was tested on Day 0 through Day 3, the fifth cholesterol addition
was detected on all 3 runs, suggesting a more consistent sensitivity. Based on the results
of both testing timelines, it was concluded that the best pre-conditioning method moving
forward consisted of testing the sensor every day from Day 0 to Day 3.

4.5

Results & Discussion
From these preconditioning optimization experiments shown, detection testing on

Day 3 was found to provide the highest sensitivity to cholesterol, and that testing every day
up to Day 3 provided the most consistency in results. Based on this, a new sensor was
functionalized and tested following the optimized pre-conditioning method. Additionally,
further improvements were made to improve performance, specifically testing the sensor
at the same time every day to ensure equal amount of testing and storage time in-between
testing. The results obtained from testing the sensor daily will be discussed in greater detail.
The average raw data from experiments performed on Day 3 and the corresponding
calibration curve are given in Figure 4.7. A summary of the data from every day of testing
is provided in Table 4.4.
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Cholesterol Detection - Day 3
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Figure 4.7 Raw data of cholesterol detection testing on Day 3. Sensor was previously
tested on Day 0, Day 1, and Day 2. First cholesterol addition added at 60 seconds and a
new cholesterol addition made every 60 seconds. The data is an average of 3
experiments.
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Day 0

Day 1

Day 2

Day 3

Slope
(mA/mM)

R2

Slope
(mA/mM)

R2

Slope
(mA/mM)

R2

Slope
(mA/mM)

R2

Run 1

-0.47

0.9915

0.04

0.6993

0.17

0.9450

0.25

0.9558

Run 2

-0.28

0.8627

0.13

0.9100

0.19

0.9393

0.28

0.9708

Run 3

-0.21

0.6498

0.16

0.9169

0.28

0.9667

0.26

0.9476

Mean

-0.32

0.8347

0.11

0.8421

0.21

0.9503

0.26

0.9581

Std
Dev

0.14

0.1726

0.06

0.1237

0.06

0.0145

0.01

0.0118

Table 4.4 Summary of slope and R2 data collected on each day of sensor testing.

The graphed raw data from Day 3 testing shows the desired step increases in
response to an increase in cholesterol concentration. The respective calibration curve
shows good linearity in the response and minimal deviation between the three
experiments. The summary of data shows that a negative slope occurred on Day 0 of
testing, further confirming this trend, and then shows that the sensitivity, or slope,
increased between each experiment and increased between each day of testing prior to
Day 3. On Day 3 of testing, the sensitivity is similar between the three experiments,
showing a good repeatability in results and an average sensitivity value of 0.26 A/mM.
Additionally, a one-way repeated measure ANOVA with an alpha of 0.05 was used to
examine the effect of testing day on sensor sensitivity. This resulted in a P-value of
5.67x10-5. Since the P-value was less than alpha it can be concluded that the day of
testing had a statistically significant effect on the sensitivity of the sensor. Further, it was
shown that the variance was the lowest on Day 3 of testing with a value of 0.0003
compared to 0.018, 0.004, and 0.003 for Day 0, Day 1, and Day 2, respectively,
confirming the greater repeatability of results on Day 3.
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An important observation made throughout all testing was the impact of the solution
on the reference electrode. Potassium ferricyanide, used as the reaction mediator in
solution, causes a reaction with the silver on-chip reference electrode, resulting in a
darkening color change. This darkening increases with the more experiments that are
performed and likely impacts the repeatability of results. Using an Ag/AgCl on chip or
glass external reference electrode might be beneficial to avoid this reaction and improve
repeatability.

4.6

Conclusion
Through the detection testing performed on the cholesterol biosensor, it was

proven that the microfluidic, chip-based biosensor for cholesterol detection was achieved.
It was shown that cholesterol changes could be detected within the physiological range of
cholesterol. This cholesterol biosensor provides a firm baseline to improve upon for
further testing.
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CHAPTER 5.
5.1

OXYGEN DETECTION BIOSENSOR

Introduction
Additional sensing capabilities were explored further with oxygen detection.

Oxygen is a critical biomarker associated with not only oxygenation of various tissues and
organs but also the redox of many crucial biochemical species in the body. Oxygen
monitoring and measurement is a key step in understanding and managing patient care and
outcomes, hence playing a critical role in many research fields and project areas. One
difficulty facing oxygen detection is dealing with ambient air and interfering external
conditions. Combining a chip-based oxygen biosensor with the previously designed
microfluidic platform could help in eliminating these difficulties. By sealing the oxygen
biosensor to the PDMS platform the environment in which the sensor surface is exposed
to is controlled, which is advantageous for results.
For the scope of this project, our goal was to expand further sensing capabilities by
creating and testing a chip-based oxygen biosensor. For this reason, the focus of this part
of the project was to implement an oxygen detection capability and not to integrate it with
the microfluidic platform, which will be delegated for future work.
This chapter discusses the biofunctionalization process of the oxygen biosensor
followed by the different methods of testing and the results of each method.

5.2

Sensor Biofunctionalization
Chip sensors composed of three screen printed electrodes (i.e., gold working

electrode, gold counter electrode and Ag/AgCl reference electrode) on a polyamide base
are used. The biofunctionalization of the working electrode is completed in three steps:
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anchoring, hydrogel layer polymerization, and creation of gas permeable membrane. The
anchoring step requires the chip sensor be submerged in a 10:1 solution of toluene and 3(trimethyoxysilyl)propyl methacrylate for 2 hours. The toluene primes the surface of the
electrodes for more effective adhesion of the subsequent hydrogel layer. The toluene
treated sensor surface is rinsed with ethanol followed by DI water. A hydrogel mixture
solution is prepared consisting of 40 wt% acrylamide, 5 wt% N,N’-methylene-bisacrylamide, 0.1 mg/ml riboflavin 5’-phosphate sodium, 1 ml/mg N,N,N’,N’-tetramethylethylenediamine, and 1:1 ratio of water to glycerol. The electrode end of the sensor is
placed into the hydrogel mixture for several seconds. A thin sheet of plastic film is used to
cover the wetted sensor surface to prevent immediate desiccation and ensure the formation
of an even hydrogel layer on the electrode surface. Before removing the plastic film, the
electrode is exposed to a UV light source for 30 minutes. A mixture solution consisting of
0.5 wt% 2,2-dimethoxy-2-phenyl-acetophenone dissolved in a 1:5 solution of acetone and
methacryloxypropyl methyl siloxane is prepared. This mixture solution is to form a of
permeable membrane on top of the hydrogel layer to separate the electrodes from
contacting the electrolyte directly while still allowing gas exchange to occur. The residue
acetone in the mixture solution is forced out by heated evaporation at 40C and the solution
is allowed to rest to rid of remaining air bubbles. To form the permeable membrane, the
electrode end of the sensor is dipped in this permeable-membrane solution mixture for
several seconds. Similarly, another piece of plastic film is placed over the solution to ensure
an even layer of the permeable membrane formation over the hydrogel layer on the
electrode. The sensor is then placed under the UV light for 24 hours, removing the plastic
film halfway through. The biofunctionalization process can be seen visually in Figure 5.1.
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Figure 5.1 Schematic of the biofunctionalization process for the oxygen biosensor.
5.3

Methods for Oxygen Detection
A negative potential is applied to the working electrode to perform the reduction of

oxygen at the working electrode, and subsequent oxidation at the counter electrode. This
can be visualized by the following reaction:
𝑂2 + 2𝐻+ + 2𝑒 − → 𝐻2 𝑂2
To assess the detection capabilities of the biofunctionalized oxygen detection biosensor
four different sets of experiments were conducted using the Keithley 2450 SourceMeter
SMU (Tektronix, Beaverton, OR, USA). Experiments were run using a three-electrode
setup, utilizing the reference, working and counter electrode on the biofunctionalized
sensor:
1. Differing the applied voltage in DI water
2. Differing the applied voltage in 4M KCl solution
3. Applying a constant voltage in different molar solutions of KCl
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4. Applying a constant voltage at different pressure settings in a vacuum chamber
The oxygen sensor was first tested under different voltages in two solutions. The
first was non-electrolyte DI water and the other is with a solution fixed concentration of
electrolyte of 4M KCl. For these tests, the sensor was placed in the respective solution and
chronoamperometric experiments were run by applying -0.2 V, -0.3 V, -0.4 V, -0.5 V, and
-0.6 V, versus Ag/AgCl reference, to the working electrode for 5 minutes each. The current
response at each applied voltage was recorded.
After that, the sensor was tested under a constant voltage in solutions of different
molar concentrations of KCl electrolyte: 1M KCl, 2M KCl, 3M KCl, and 4M KCl. For
these tests, the sensor was placed in each of the four KCl solutions and
chronoamperometric experiments were run by applying -0.5 V, versus Ag/AgCl reference,
for 5 minutes each. The current response at each molar concentration of KCl was recorded.
The oxygen sensor was further tested in a controlled pressure chamber under a
constant working electrode potential in DI water. To do that, the sensor was placed in a
beaker of DI water sitting in a vacuum chamber. Chronoamperometric experiments were
run by applying -0.3 V versus Ag/AgCl reference for 2 minutes at six preselected pressure
settings: -0.1, -0.2, -0.3, -0.4, -0.5 and -0.6 bar. These pressure readings, converted to
mmHg and kPa, along with the corresponding oxygen partial pressure in mmHg are listed
in Table 5.1.
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Bar

Relative bar

Relative mmHg

O2 Partial
Pressure (mmHg)

kPa

-0.6

0.413

310

65.10

-60

-0.5

0.513

385

80.85

-50

-0.4

0.613

460

96.60

-40

-0.3

0.713

535

112.35

-30

-0.2

0.813

610

128.10

-20

-0.1

0.913

685

143.85

-10

Table 5.1 Pressure conversions and oxygen content for experiments performed on oxygen
detection biosensor at different pressures in vacuum chamber.
5.4

Results & Discussion
The raw data of average current response of the oxygen sensor in DI water to changes

in voltage is shown in Figure 5.2. The raw data for the other three experimental conditions
is given in Appendix B. The response curves follow the trend of the Cottrell decay curve,
only reversed, which is to be expected. If a positive potential is applied to the system, the
decay curve is the result. Whereas, if a negative potential is applied a saturation curve
occurs, as shown in Figure 5.2. This represents what a typical measurement looks like. The
steady state current values from the raw data are then used to create the calibration curves.
The calibration curve for the oxygen detection performed in DI water is shown in Figure
5.3, and it provides a correlation coefficient of 0.98. This suggests that the magnitude of
the current response linearly increases with increasing voltage.
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Average Current at Differing Voltages in DI Water
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Figure 5.2 Raw data of the amperometric current response of the biosensor in DI water at
different applied voltages.

Average Steady State Current at Differing Voltages in DI Water
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Figure 5.3 Final, steady state average current response of the oxygen biosensor in DI
water at different applied voltages.
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As compared with the previous results of current response in DI water, the linearity
between current response and voltage change in 4M KCl is lower at 0.8889. However, due
to the magnitude of the current responses, the slope of the trendline is higher showing a
higher sensitivity to changes in oxygen in 4M KCl solution. The sensitivity to change in
4M KCl solution is 142.96% higher than in DI water, indicative of the enhanced mass
transport by the presence of the electrolyte.
Average Steady State Current at Differing Votlages in 4M KCl
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Figure 5.4 Final, steady state average current response of the oxygen biosensor in 4M
KCl solution at different applied voltages.

The calibration curve in response to the oxygen detection performed in different molarities
of KCl solution is shown in Figure 5.5. This provides a correlation coefficient of 0.9814,
indicating a linear correlation between KCl concentration and current response. As the
molarity of the KCl solution was increase, the magnitude of the resulting current response
also increased.
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Figure 5.5 Final, steady state average current response of the oxygen biosensor in
different molar concentrations of KCl solution.

For measurements taken at different pressure settings in a vacuum chamber, the pressure
was converted from Bar (unit of vacuum chamber) to mmHg (oxygen content) and steady
state current was plotted against this value (Figure 5.6). The linearity was high, 0.9842,
indicating a linear relationship between current and pressure, and therefore a linear
relationship between current and oxygen concentration. As the oxygen content increases,
the magnitude of the current increases, showing that the oxygen detection sensor is
functioning properly in detecting changes in oxygen. The normal arterial oxygen partial
pressure is within 75-100 mmHg. The results confirm the capability of the developed
oxygen sensor to detect changes in oxygen content within this physiological range.
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Final Steady State Current at Different O2 Content
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Figure 5.6 Final, steady state average current response at different amounts of oxygen
content. The reading, in units of Bar, on the vacuum chamber was converted to mmHg to
determine oxygen content.

5.5

Conclusion
Through the different tests performed to the oxygen biosensor, it was shown that the

biosensor could detect changes in oxygen concentration in solution.
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CHAPTER 6.
6.1

CONCLUSIONS AND FUTURE WORK

Conclusions
This work has demonstrated the success of a microfluidic, chip-based biosensor for

the detection of different critical biomarkers. Through the timeline of this project and the
effort for continuous improvement, we were able to combine microfluidics with an
amperometric biosensor. We were also able to prove the capability of the biosensor to
detect different targets, mainly glucose, cholesterol, and oxygen. This design provides a
desirable platform due its reusability, the small volume of solution needed, and the
continuous flow of solution, which would allow for continuous monitoring in a research
and clinical setting. Additionally, this platform would provide a more cost effective and
easy-to-deploy method for biomarker detection than what is currently used for the
measurement and monitoring of many critical biomarkers.

6.2

Future Work
Further evaluation should be done on the cholesterol biosensor to optimize the pre-

conditioning and testing timeline of the sensor for improved sensitivity. Additionally,
modifications should be made to the reference electrode to prevent the reaction with the
mediator in solution and improve the repeatability of results. This could be done by
modifying the on-chip electrode or adapting the microfluidic platform design to include
an external glass reference electrode.
An optimal design would include the possibility to perform detection of multiple
biomarkers simultaneously, or a multi-target device. To facilitate this, future work includes
expansion of the current microfluidic, chip-based platform design to create a device
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consisting of multiple functionalized sensors to allow for simultaneous biomarker
detection and monitoring. This would allow for glucose, cholesterol, and oxygen detection
and monitoring within one device. Based on the intended use and what is needed, the
detection of other biomarkers using this platform should be explored. This could provide
a device that can be customized based on the multi-target detection needs.
Further testing should also be done to evaluate the specificity of the biosensors to the
biomarker in question to examine their practical application capabilities. Testing of each
biosensor was performed without or with minimal potential interference substances in
solution. It is important to test these further to determine the sensors response when
multiple substances are present in solution, such as in human blood or serum.
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APPENDICES
6.3

APPENDIX A. OXYGEN SENSOR RAW DATA

Raw data of the amperometric current response of the biosensor in 4M KCl solution at
different applied voltages.

Raw data of the amperometric current response of the biosensor in different molarities of
KCl solution at a constant applied voltage.
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Raw data of the amperometric current response of the biosensor in DI water at different
pressures in a vacuum chamber.
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6.4

APPENDIX B. LABORATORY PROCEDURES

RCA-1 Cleaning Procedure for Sensor
Solution: 5 parts water, 1 part NH4OH, 1 part H2O2
Procedure:
1. Add 10 mL DI water and 2 mL 27% ammonium hydroxide (NH4OH) to Pyrex
glass beaker.
2. Heat to 70 +/- 5 degrees Celsius on hot plate (~25 min. using hot plate with external
temp. probe).
3. Once heated, turn off hot plate and add 2 mL 30% hydrogen peroxide (H2O2).
4. Solution will bubble vigorously after 1-2 min., indicating its ready for use.
5. Using a Q-tip, add solution to only the working and counter electrode. Every 3
minute remove the solution with the Q-tip and replace the solution. Continue this
for a total of 15 minutes.
6. Transfer solution to a beaker with cold water to cool.
7. Rinse the sensor multiple times with DI water and let dry.
8. Once solution in DI water has cooled, pour down the drain with plenty of cold water
to flush (let water run for 5 minutes). Rinse all lab ware 3 times in cold water.
Glucose Sensor Functionalization – Beaker Method
Procedure:
1. Chill 5mL PBS in the 10mL glass beaker in the refrigerator for 5 minutes.
2. Remove and use spoon scoop to weigh and add 0.005g of GOx, stir solution.
3. Use the pipet to add 35 µL of pyrrole and thoroughly stir solution.
4. Tape over the counter and reference electrodes of the sensor with scotch tape
5. Turn on the potentiostat.
6. Connect the working/working sense lead of the potentiostat together and connect
to the working wire of the sensor cable and place the sensor in the beaker solution.
7. Connect the reference/counter lead together and connect to the platinum gauze and
place the gauze into the solution, close to the working electrode without touching
it.
8. Run a chronopotentiometry experiment at 10A, 0.2 time per point, for 420 seconds
for AT electrode and 270 seconds for BT electrodes.
a. The deposition should be as even as possible and darkened but not
completely (gold should still be visible through) (AT left, BT right).
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Glucose Sensor Functionalization – PDMS Well Method
Procedure:
1. Create the deposition solution by adding 0.002g of glucose oxidase (GOx) and
14.4µL of pyrrole to 1mL chilled PBS in a 10mL glass beaker, thoroughly stir
solution.
2. Put solution into syringe with purple blunt tip needle.
3. Cut a piece of conductive tape in half lengthwise (to make it thinner) and wrap
around the needle leaving excess to be attached to the counter lead, folding over to
hide sticky section.
4. Turn on the potentiostat and connect the working and working sense leads together
and the reference and counter leads together.
5. Secure the PDMS well to the sensor by using the clamps and wood board, and
connect the sensor to the CAC cable.
6. Secure syringe to clamp on the stand and lower into the PDMS well, close to the
working electrode without touching it.
7. Attach the counter/reference lead to the conductive tape and the working/working
sense lead to the working lead of the CAC cable.
8. Press the syringe to fill the well with solution (initially fill ½ to ¾ of the way full)
a. The needle should be partially submerged, and the solution shouldn’t touch
the conductive tape.
9. Choose new chronopotentiometry experiment.
10. Run a chronopotentiometry experiment at 10µA in 1-minute increments.
a. After each minute increase the liquid in the well.
b. Every 3 minutes remove solution from well with a separate syringe and
refill the well.
c. Visually inspect working electrode after minute runs. Should be darkened
but still visible gold showing through.
Glucose Detection – Low Glucose Concentration Range (Beaker Method)
Procedure:
1. Make a 0.1M PBS solution containing 3mM p-Benzoquinone by adding 0.0066g
of p-Benzoquinone to 20mL PBS in a 20mL glass beaker.
2. Remove the functionalized sensor from the refrigerator and clip sensor into the
CAC cable and place sensor inside the 10mL beaker. Ensure the sensor remains
vertical.
3. Using a 1mL syringe, add 5mL of the PBS/p-Benzoquinone solution to the beaker
with the sensor.
4. Turn on the potentiostat and allow a minute for boot up.
5. Open up the VersaStudio software and select choose instrument. Choose the
corresponding instrument. Create a new experiment and choose
chronoamperometry.
6. Attach the 3 potentiostat leads to the 3 sensor cable leads.
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7. The sense lead should be connected to the working lead and both ground cables
should be left disconnected.
8. Let the sensor sit in the solution, connected, for pre-conditioning for 30 minutes.
9. During the 30 minutes – In a separate beaker, create a 1M glucose solution by
adding 0.9008g of glucose to 5mL DI water.
10. After the 30 minutes – on the VersaStudio screen – enter in the following
parameters: Potential (V) = 0.35V vs ref, Time Per Points (s) = 0.2, Duration (s) =
1500
11. Leave all other parameters as is
12. Start the experiment by pressing the run button in VersaStudio.
13. Let run for 15 minutes (900 seconds) for current to even out, then add glucose
solution to the beaker on the 15-minute mark.
a. 5 µL additions for physiological range
b. Larger additions for higher range (use glucose concentration calculator for
desired amount)
14. Make additions of glucose solution each consecutive minute.
15. Perform manual stirring using the pipette.
16. Save and copy data and paste into excel.
17. Return the sensor back to dry refrigerator storage (in Ziploc bag) after use.
Glucose Detection – High Glucose Concentration Range (24-Well Plate Method)
Procedure:
1. Make a 0.1M PBS solution containing 3mM p-Benzoquinone by adding 0.0033g
of p-Benzoquinone to 10mL PBS in a 20mL glass beaker.
2. Remove the sensor from the refrigerator and clip sensor into the CAC cable and
place sensor inside one of the wells on the plate. Ensure the sensor remains vertical.
3. Using a 1mL syringe, add 1.5mL of the PBS/p-Benzoquinone solution to the well
with the sensor.
4. Turn on the potentiostat and allow a minute for boot up.
5. Open up the VersaStudio software and select choose instrument. Choose the
corresponding instrument. Create a new experiment and choose
chronoamperometry.
6. Attach the 3 potentiostat leads to the 3 sensor cable leads.
7. The sense lead should be connected to the working lead and both ground cables
should be left disconnected.
8. Let the sensor sit in the solution with continuous measurement for 30 minutes.
9. During the 30 minutes – In a separate beaker, create a 1M glucose solution by
adding 0.9008g of glucose to 5mL DI water.
10. After the 30 minutes – on the VersaStudio screen – enter in the following
parameters: Potential (V) = +0.35V vs ref, Time Per Points (s) = 0.2, Duration (s)
= 1500.
11. Leave all other parameters as is.
12. Start the experiment by pressing the run button in VersaStudio.
13. Let run for 15 minutes (900 seconds) for the current to level out, then add 30µL of
glucose solution to the well on the 15-minute mark.
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14. Make 30 µL additions of glucose solution each consecutive minute.
15. Perform manual stirring using the pipette.
16. Save and copy data and paste into excel.
17. Return the sensor back to dry refrigerator storage (in a Ziploc bag) after use.
Glucose Detection – Manual Solution Flow
This method utilizes the liquid capacity of the sensor when lying flat on a surface.
Procedure:
1. Make a 0.1M PBS solution containing 3mM p-Benzoquinone by adding 0.0066g
of p-Benzoquinone to 20mL PBS in a 20mL glass beaker.
2. In a 10mL beaker, create a 1M glucose solution by adding 0.9008g of glucose to
5mL DI water.
3. Create 10 different solutions using the solutions above and the below chart:

Solution #

PBS soln.
Glucose (µL)
(mL)

Molarity (mol/L)

Clinical (mg/dL)

1

1.5

5

0.0033223

59.8

2

1.5

7

0.0046451

83.6

3

1.5

9

0.0059643

107.4

4

1.5

11

0.0072801

131

5

1.5

15

0.0099012

178.2

6

1.5

20

0.0131582

236.8

7

1.5

25

0.0163938

295.1

8

1.5

35

0.0228018

410.4

9

1.5

45

0.0291269

524.3

10

1.5

50

0.0322588

580.7

4. Remove the functionalized sensor from the refrigerator, attach to the CAC cable
and secure flat to the platform.
5. Turn on the potentiostat and allow a minute for boot up.
6. Open up the VersaStudio software and select choose instrument. Choose the
corresponding instrument. Create a new experiment and choose
chronoamperometry.
7. Attach the 3 potentiostat leads to the 3 sensor cable leads.
8. Using a pipette, dispense 70 µL of the PBS/p-benzoquinone solution onto the
sensor.
9. Let sit for pre-conditioning for 5 minutes.
10. On the VersaStudio screen – enter in the following parameters: Potential (V) =
+0.35V vs ref, Time Per Points (s) = 0.2, Duration (s) = 900 (15 minutes)
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11. Start the experiment by pressing the run button in VersaStudio.
12. Let the experiment run for 300 seconds (5 min) to allow the current to even out,
then at 300 seconds use two pipettes to replace the solution (1 to remove the
solution on the sensor and the 2nd to add the new concentration), continue this on
each minute mark, increasing the concentration as you go.
13. Rinse the sensor with DI water and store in a ziploc bag in the refrigerator.
Glucose Detection – Microfluidic, Chip-Based
Procedure:
1. Make a 0.1M PBS solution containing 3mM p-Benzoquinone by adding 0.0066g
of p-Benzoquinone to 20mL PBS in a 20mL glass beaker.
2. In a 10mL beaker, create a 1M glucose solution by adding 0.9008g of glucose to
5mL DI water.
3. Create 10 different solutions in 10 separate beakers using the solutions above and
the below chart:
Solution #

PBS soln.
Glucose (µL)
(mL)

Molarity (mol/L)

Clinical (mg/dL)

1

1.5

5

0.0033223

59.8

2

1.5

7

0.0046451

83.6

3

1.5

9

0.0059643

107.4

4

1.5

11

0.0072801

131

5

1.5

15

0.0099012

178.2

6

1.5

20

0.0131582

236.8

7

1.5

25

0.0163938

295.1

8

1.5

35

0.0228018

410.4

9

1.5

45

0.0291269

524.3

10

1.5

50

0.0322588

580.8

4. Attach the sensor/microfluidic platform to the pump and CAC cable.
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5. Pump through 100 microL of PBS/p-Benzoquinone solution to cover the electrodes
and stop the pump right before the well empties of solution. Perform
preconditioning for 5 minutes by connecting the CAC cable leads to the working,
counter and reference leads of the PARSTAT MC and letting sit for 5 minutes.
6. Start a new chronoamperometry experiment at +0.35V, 0.2 time per points, and 900
seconds
7. At 300 seconds, add 100 microL of the first PBS/p-Benzoquinone/glucose addition
solution and start the pump
8. Add 100 microL on each minute after, increasing from the lowest to highest
concentration.
9. Save, copy and paste data into excel.
10. Store the sensor attached to the PDMS platform in the refrigerator.
Cholesterol Sensor Functionalization
Procedure:
1. Create the deposition solution by adding one 25U bottle of cholesterol oxidase
(ChOx) and 14.4µL of pyrrole to 1mL chilled PBS in a 10mL glass beaker,
thoroughly stir solution.
2. Put solution into syringe with purple blunt tip needle.
3. Cut a piece of conductive tape in half lengthwise (to make it thinner) and wrap
around the needle leaving excess to be attached to the counter lead, folding over to
hide sticky section.
4. Turn on the PARSTAT MC and connect the working and working sense leads
together and the reference and counter leads together.
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5. Secure the PDMS well to the sensor by using the clamps and wood board, and
connect the sensor to the CAC cable.
6. Secure syringe to clamp on the stand and lower into the PDMS well, close to the
working electrode without touching it.
7. Attach the counter/reference lead to the conductive tape and the working/working
sense lead to the working lead of the CAC cable.
8. Press the syringe to fill the well halfway with solution.
a. The needle should be partially submerged, and the solution shouldn’t touch
the conductive tape.
9. Choose new chronopotentiometry experiment.
10. Run a chronopotentiometry experiment at 10µA in 1-minute increments for 7-8
minutes depending on visual inspection.
a. After each minute increase the liquid in the well. Should follow the pattern:
half filled, run experiment, fully filled, run experiment, run experiment
again fully filled, then remove solution and replace to half filled with new
solution.
b. So, every 3 minutes remove solution from well with a separate syringe and
refill the well
c. Visually inspect working electrode after minute runs. Should be darkened
but still visible gold showing through.
Cholesterol Detection – Microfluidic, Chip-Based
Procedure:
1. The Verichem Matrix Plus Cholesterol Reference kit is used for the cholesterol
testing concentrations.
2. Using 5 separate 10mL glass beakers, dispense 5 drops (~140L) of each solution
into each beaker.
a. Before dispensing of each solution into the individual beakers, drop one
drop from each bottle into a beaker for later disposal.
3. The 5 different solutions are pre-determined as follows:

A

Cholesterol
(mg/dL)
40

B
C
D
E

Solution Level

0.001034

Uric Acid
(mg/dL)
2

155

0.004008

7

270
385
500

0.006982
0.009956
0.012930

12
17
22

Cholesterol (M)

4. Create supporting electrolyte / redox mediator solution by adding 0.033 g of
potassium ferricyanide to 10 mL PBS and mix. This is a 10mM [Fe(CN6)]3solution.
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5. Add 100 L of the solution in step 4 into each individual beaker from step 2 and
mix.
6. Attach the sensor/microfluidic platform to the pump and CAC cable.

7. Set the pump to a withdraw rate of 0.2 mL/min and pump through 300 L of the
solution from step 4 to cover the electrodes and stop the pump right before the well
empties of solution. Perform preconditioning for 45 minutes by connecting the
CAC cable leads to the working, counter and reference leads of the PARSTAT MC
and letting sit for 45 minutes.
8. Start a new chronoamperometry experiment at +0.60V, 0.2 time per points, and 600
seconds.
a. IMPORTANT: set the current range to 20 A. Don’t leave it on auto.
9. At 60 seconds, add 200 L of the first cholesterol addition solution and start the
pump (this is two separate 100 L additions).
10. Add 200 L on each minute after, increasing from the lowest to highest
concentration.
11. Save, copy and paste the data into excel.
12. Store the sensor attached to the PDMS platform in the refrigerator.
Oxygen Sensor Functionalization
Procedure:
Anchoring method
1. 20mL of toluene and 2mL of 3-(trimethyoxysilyl)propyl methacrylate were added
to a 20 mL beaker.
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2. Submerge the electrode in the beaker (make sure all electrodes are covered) for at
least 2 hours.
3. Remove the electrode from solution and rinse with ethanol, then with DI water.
4. Let air dry before adding hydrogel layer.
Hydrogel Layer
1. Add 2.5 mL of DI water to a 20 mL beaker.
2. Add a stir bar and place the beaker on a stir plate.
3. Add 2.264g of acrylamide to the beaker and stir until completely dissolved.
4. Add 0.269g of N, N’-methylene-bis-acrylamide to the beaker and stir until
completely dissolved.
5. Add 2.5 mL of glycerol to the beaker and stir until dissolved.
6. Add 0.0051g of Riboflavin 5’-phosphate sodium and 6 µL of N, N, N’, N’tetramethyl-ethylenediamine into the beaker and stir until dissolved (After these
two chemicals are added, speed is necessary as the hydrogel will start to polymerize
quickly. Make sure the electrode is ready before adding these two chemicals).
7. As soon as the Riboflavin 5’-phosphate sodium and N, N, N’, N’-tetramethylethylenediamine dissolve, stick the electrode end of the sensor into the hydrogel
mixture.
8. After several seconds, pull the electrode out.
9. Make sure the hydrogel is in an even, thin layer by placing a small piece of plastic
film over the hydrogel layer.
10. Place the electrode under a UV light source for 30 minutes.
11. Make the permeable membrane solution while you are waiting for the hydrogel to
polymerize.
12. Remove the thin film from the electrode.
Permeable Membrane
1. Add 0.0261g of 2,2-dimethoxy-2-phenyl-acetophenone into a 20 mL beaker.
2. Add 1 mL of acetone to the beaker and stir, by hand, until dissolved.
3. Add 5 mL of Methacryloxypropyl methyl siloxane (measure with a graduated
cylinder) into the beaker and stir by hand.
4. Place the beaker in a 40°C oven to evaporate the acetone.
5. The beaker needs to rest, wrapped in aluminum foil until the bubbles created during
stirring disappear.
6. Place the electrode end of the sensor into the membrane mixture.
7. After several seconds, pull the electrode out and let the excess mixture drip off.
8. Place a piece of the plastic film over the membrane and carefully smooth the surface
until an even thin film forms over the hydrogel.
9. Place the electrode under a UV light source for 12 hours.
10. Remove the thin film and leave the sensor under the light source for 12 hours.
11. Attach wires to each electrode strip using conductive tape.
12. Cover the connected wires with microstop to seal.
Oxygen Sensor Testing – Applying Different Voltages
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Procedure:
Testing in DI water:
1. Place sensor inside the 10mL beaker containing 5mL DI water.
2. Turn on the potentiostat and allow a minute for boot up.
3. Open up the VersaStudio software and select choose instrument. Choose the
corresponding instrument. Create a new experiment and choose
chronoamperometry.
4. Attach the 3 potentiostat leads to the 3 wires attached to the sensor.
5. The sense lead should be connected to the working lead and both ground cables
should be left disconnected.
6. Let the sensor sit connected for pre-conditioning for 3 minutes.
7. On the VersaStudio screen – enter in the following parameters: Time Per Points (s)
= 0.2, Duration (s) = 300
a. The voltage changes with each experiment: -0.2V, -0.3V, -0.4V, -0.5V, and -0.6V
8. Leave all other parameters as is.
9. Start the experiment by pressing the run button in VersaStudio.
10. Save and copy data and paste into excel.
11. Store the sensor in a Ziploc bag at room temperature.
Testing in 4M KCl solution:
1. Make a 4M KCl solution in DI water in a 20mL beaker with 5.964g KCl and 20mL
DI water.
2. Turn on the potentiostat and allow a minute for boot up.
3. Open up the VersaStudio software and select choose instrument. Choose the
corresponding instrument. Create a new experiment and choose
chronoamperometry.
4. Attach the 3 potentiostat leads to the 3 wires attached to the sensor and place sensor
inside the beaker containing 4M KCl.
5. The sense lead should be connected to the working lead and both ground cables
should be left disconnected.
6. Let the sensor sit connected for pre-conditioning for 3 minutes.
7. On the VersaStudio screen – enter in the following parameters: Time Per Points (s)
= 0.2, Duration (s) = 300
a. The voltage changes with each experiment: -0.2V, -0.3V, -0.4V, -0.5V, and
-0.6V
8. Leave all other parameters as is.
9. Start the experiment by pressing the run button in VersaStudio.
10. Save and copy data and paste into excel.
11. Store the sensor in a Ziploc bag at room temperature.
Oxygen Sensor Testing – Constant Voltage in Different Molarities of KCl Solution
Procedure:
1. Make a 4M KCl solution in DI water in a 20mL beaker by adding 5.964g KCl to
20mL DI water.
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2. Stir using stir bar until fully dissolved.
3. Turn on the potentiostat and allow a minute for boot up.
4. Open up the VersaStudio software and select choose instrument. Choose the
corresponding instrument. Create a new experiment and choose
chronoamperometry.
5. Attach the 3 potentiostat leads to the 3 wires attached to the sensor and place the
sensor in the beaker containing KCl solution.
6. The sense lead should be connected to the working lead and both ground cables
should be left disconnected.
7. Let the sensor sit connected for pre-conditioning for 3 minutes.
8. On the VersaStudio screen – enter in the following parameters: Voltage = -0.5V,
Time Per Points (s) = 0.2, Duration (s) = 300
9. Leave all other parameters as is.
10. Start the experiment by pressing the run button in VersaStudio.
11. Save and copy data and paste into excel.
12. Repeat steps 1-12 for different molarities of KCl dissolved in 20mL DI water:
a. 1M: 1.491g KCl
b. 1.5M: 2.237g KCl
c. 2M: 2.982g KCl
d. 2.5M: 3.7275g KCl
e. 3M: 4.473g KCl
f. 3.5M: 5.2185g KCl
13. Store the sensor in a Ziploc bag at room temperature.
Oxygen Sensor Testing – Different Pressures in a Vacuum Chamber
Procedure:
1. Create the seal on the rim of the vacuum chamber by placing a piece of scotch tape
over the rim (a couple inches across) and placing a thin layer of putty over the tape.
2. Place the sensor in a beaker of DI water inside the vacuum chamber and seal the
chamber to -0.8 bar.
3. Place putty externally around where the sensor and tape are.
4. Connect the three wires attached to the sensor to the three leads of the potentiostat.
5. Decrease the vacuum to –0.1 bar.
6. Let the connected sensor sit for pre-conditioning for 5 minutes.
7. Run a chronoamperometry experiment at -0.3V for 120 seconds.
8. Copy and Save data.
9. Repeat steps 6-8 at -0.2, -0.3, -0.4, -0.5, and -0.6 bar.
PDMS Well
Procedure:
Platform Setup:
1. Attach multiple 3D wells, spread out, to the petri dish using silicone sealant
PDMS:
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1. Use the scale to measure out a 10:1 ratio of silicone elastomer base to elastomer
curing agent in a weigh dish.
2. Stir the solution until mixed (will be very bubbly) for 5-10minutes depending on
how much you make.
3. Pour the solution into two centrifuge tubes (equal amounts in each tube) (if more
tubes are needed use an even number so that its symmetrical in the centrifuge
machine).
4. Place the tubes symmetrically into the centrifuge.
5. Run the centrifuge at 3200 rpm for 2 minutes.
6. Remove the tubes from the machine. The bubbles should be removed, and the
solution should be clear.

PDMS pouring:
1. Pour the PDMS into the petri dish until in line with the top of the 3D printed wells.
2. Ensure there are no bubbles in the PDMS from pouring. The small bubbles will
disperse on their own. A needle can be used to extract the large bubbles if
necessary.
3. Leave to fully cure for 48 hours.
Removal:
1. Once fully cured, remove the PDMS from the petri dish (this can be done using a
blade and going around the edges or by breaking the petri dish).
2. The 3D printed wells can then be removed gently by hand and the PDMS can be
cut into individual PDMS wells.
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PDMS Microfluidic Platform
Procedure:
Platform Setup:
1. Mold the inlet channels using the 0.5mm extruded PLA material and the soldering
iron. Attach the 0.5mm bar to the end of the soldering iron using masking tape and
turn the soldering iron on to setting 3.
2. Once heated, take the 0.5mm extruded PLA and bend over the 0.5mm bar to form
a 90-degree angle. Remove quickly and hold in shape until cooled (a few seconds).
Do this twice so that you have two inlet channels.
3. Cut straight pieces of the 0.5mm extruded PLA material to use as the outlet
channels.
4. To attach the channels to the disk, dip the section you want to attach into the acetone
and place it onto the disk. It will attach as it dries. Do this for the inlet and outlet
channels. Stagger the inlet and outlet channels on the disk so they are not directly
in line with each other
5. Attach the channels and disk to the sensor by placing a small amount of silicone
sealant on the working electrode and placing the disk on top. Press firmly to ensure
placement.
6. Secure each sensor to the petri dish by placing silicone sealant on the back of the
sensor and placing the sensor on the petri dish. Press firmly to ensure placement.
7. The two sensors should be placed in opposite directions.
8. Let the acetone completely evaporate while you make the PDMS.
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PDMS:
1. Use the scale to measure out a 10:1 ratio of silicone elastomer base to elastomer
curing agent in a weigh dish.
2. Stir the solution until mixed (will be very bubbly) for 5-10minutes depending on
how much you make.
3. Pour the solution into two centrifuge tubes (equal amounts in each tube) (if more
tubes are needed use an even number so that its symmetrical in the centrifuge
machine).
4. Place the tubes symmetrically into the centrifuge.
5. Run the centrifuge at 3200 rpm for 2 minutes.
6. Remove the tubes from the machine. The bubbles should be removed, and the
solution should be clear.

First Round of PDMS:
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1. Pour the PDMS into the petri dish covering the sensor chips and disks. The petri
dish should be about half full.
2. Ensure there are no bubbles in the PDMS from pouring. The small bubbles will
disperse on their own. A needle can be used to extract the large bubbles if
necessary.
3. Leave to partially cure for ~24 hours.

Second Round of PDMS:
1. Once the first pour is partially cured, 3D printed PLA wells need to be placed. The
PDMS is still sticky when partially cured, which allows the PLA wells to be placed
without moving.
2. Cut down the PLA to be in line with the PDMS.
3. Place each PLA well centered above the inlet channels for each. Press slightly to
ensure the well is in place on the sticky PDMS.
4. Make another batch of PDMS following the above steps.
5. Pour the PDMS on top of the partially cured PDMS. Stop pouring once the PDMS
is in line with the top of the PLA well.
6. Remove any bubbles if necessary.
7. Let the PDMS cure for 48 hours.
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Removal:
1. Once fully cured, remove the PDMS from the petri dish (this can be done using a
blade and going around the edges or by breaking the petri dish).
2. The sensor can be removed from the PDMS by hand (gently), along with the disk.
3. The PLA channels can either be removed by gently pulling (if there is no
resistance), or the platform can be soaked in acetone overnight and a syringe can
be used to remove the remaining PLA.
4. Once removed, use a syringe to pump DI water through the system to ensure all
channels are open and connected. A needle can be used to open/connect any
channels if needed.
5. The platform can then be sliced in half using a blade to create the two separate
microfluidic platforms.

Cyclic Voltammetry Experiments on Blank Electrodes
Procedure:
1. Clean electrodes using the RCA-1 method.
2. Prepare solution of 5 mM potassium ferricyanide in PBS by adding 0.01646 g of
potassium ferricyanide to 10 mL PBS.
3. Set up the sensor by attaching the sensor to the CAC cable and placing the sensor
inside the beaker of solution. Place a stir bar inside beaker and place on stir plate.
4. Attach platinum gauze (external counter electrode) to the counter lead of the
potentiostat and place in solution close to sensor electrodes.
5. Attach external glass reference electrode to the reference lead of the potentiostat
and place in solution close to sensor electrodes.
6. Run a cyclic voltammetry (multiple cycles) experiment with a potential range of
+0.7V to -0.15V and 20 cycles.
7. Run at the selected scan rate (50 mV/s, 100 mV/s, 150 mV/s, 200 mV/s) and adjust
the stir bar speed accordingly.
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